WO2024201041A2 - Compositions probiotiques et postbiotiques, produits et leurs utilisations - Google Patents

Compositions probiotiques et postbiotiques, produits et leurs utilisations Download PDF

Info

Publication number
WO2024201041A2
WO2024201041A2 PCT/GB2024/050842 GB2024050842W WO2024201041A2 WO 2024201041 A2 WO2024201041 A2 WO 2024201041A2 GB 2024050842 W GB2024050842 W GB 2024050842W WO 2024201041 A2 WO2024201041 A2 WO 2024201041A2
Authority
WO
WIPO (PCT)
Prior art keywords
clostridium
composition
strain
accession number
deposited under
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2024/050842
Other languages
English (en)
Other versions
WO2024201041A3 (fr
Inventor
Christopher Stewart
Janet BERRINGTON
Nicholas EMBLETON
Jonathan Chapman
Andrea Masi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Newcastle University
Original Assignee
Newcastle University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newcastle University filed Critical Newcastle University
Priority to EP24717762.9A priority Critical patent/EP4687932A2/fr
Publication of WO2024201041A2 publication Critical patent/WO2024201041A2/fr
Publication of WO2024201041A3 publication Critical patent/WO2024201041A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals

Definitions

  • the present invention provides a probiotic composition for improving the gut microbiome and/or gut health of a subject comprising at least one Clostridium species selected from Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum. It also provides postbiotic compositions from these Clostridium species for the same purpose. Products comprising the compositions and methods of using the compositions are also provided herein.
  • the bacteria and other microorganisms that colonise the gut play important roles in health and disease. This is especially true during the first year of life, where the gut microbiome contributes to education and training of the immune system, which can have implications for long term health.
  • Receipt of breast milk is one of the most important modulators of the infant gut microbiome, due in part to the direct provision of prebiotics.
  • Prebiotics are non-digestible substrates that promote the growth of beneficial bacteria, termed probiotics, and an example of prebiotics in breast milk is human milk oligosaccharides (HMOs).
  • HMOs are abundant unconjugated sugars that reach the infant gut intact where they are consumed by selected probiotic bacteria.
  • SCFAs short chain fatty acids
  • NICU neonatal intensive care unit
  • the preterm infant gut microbiome is less diverse, less stable, contains lower abundance of potentially probiotic bacteria, and a higher abundance of pathobiont bacteria. This altered gut microbiome has been associated with poorer health and an increased risk to several life-threatening diseases.
  • Probiotics that contain Bifidobacterium species that can utilise HMOs have been used in many NICUs worldwide and overall meta-analyses suggests they can reduce disease risk, primarily relating to late onset sepsis (LOS) and necrotising enterocolitis (NEC).
  • LOS late onset sepsis
  • NEC necrotising enterocolitis
  • the invention is based on the surprising finding that several bacterial species of the Clostridium genus utilise HMOs and therefore represent beneficial probiotics for improving the gut microbiome and/or gut health of a subject.
  • the inventors have surprisingly discovered that Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum utilise a number of HMOs when in co-culture, including at least one of: LNnT, LNT, 6SL, 2FL, DLSNT and LNFPJ.
  • HMO-utilising bacteria When grown on HMOs, HMO-utilising bacteria produce short chain fatty acids, convert aromatic amino acids into aromatic lactic acids (for example indolelactic acid (ILA)) and release other functionally important compounds that have significant beneficial immunomodulatory roles in the health of a subject.
  • ILA indolelactic acid
  • ILA has been shown to limit T cell activation and reduce a pro-inflammatory response by inducing galectin-1 in TH2 and TH 17 cells during helper T cell polarisation. Accordingly, consumption of compositions that comprise one or more of these Clostridium species will therefore provide health benefits to a subject.
  • Clostridium perfringens is an abundant and prevalent species present in the gut in early life and is present at higher levels in healthy infants compared to infants diagnosed with necrotising enterocolitis (NEC) during the critical window of NEC risk (the first 10 to 40 days of life). Furthermore, the inventors have demonstrated that Clostridium perfringens is more abundant in the gut of healthy infants compared to infants before they were diagnosed with NEC, but not after recovery from NEC. This suggests that Clostridium perfringens plays an important role in protecting against NEC and suggests that increased levels of Clostridium perfringens in the gut would be beneficial and protective against disease.
  • NEC necrotising enterocolitis
  • the data provided herein indicates that a probiotic composition comprising one or more bacterial species of the Clostridium genus would improve the gut microbiome in a subject.
  • all of Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum have been shown to utilise at least one HMO, including LNnT, LNT, 6SL, 2FL, DSLNT and/or LNFPJ, thus sharing a common metabolic pathway and production of, for example, short chain fatty acids.
  • Clostridium perfringens is more abundant in the gut of healthy infants compared to infants before they were diagnosed with NEC, which suggests that such a protective effect would be present for other diseases affecting, for example, the gastrointestinal tract.
  • Clostridium perfringens in disease outcome for NEC, other therapeutic outcomes are dependent on probiotic levels and as such, it is also reasonable that one or more bacterial species of the Clostridium genus including Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum would be therapeutically beneficial in preventing or treating any disorder that is exacerbated by probiotic imbalance, such as a gastrointestinal disorder, allergy, nappy rash, and colic, or a symptom thereof.
  • Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum can advantageously reduce pathogen overgrowth in the gut, promote gut development, promote gut maturation, promote immunity, decrease gut inflammation, and/or promote enteral feeding tolerance in the subject.
  • the invention provides a probiotic composition for improving the gut microbiome and/or gut health of a subject, the composition comprising at least one Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum; further comprising at least one prebiotic; wherein the prebiotic is a mammalian milk oligosaccharide (MMO), a precursor and/or a derivative thereof.
  • MMO mammalian milk oligosaccharide
  • the composition may comprise at least two Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum.
  • the composition may comprise at least three Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum.
  • the composition may comprise at least 0.5 x 10 9 CFU Clostridium species per dose.
  • the MMO may be a human milk oligosaccharide (HMO) a precursor and/or a derivative thereof.
  • HMO human milk oligosaccharide
  • the HMO may be selected from the group consisting of: lacto-N-tetraose (LNT), lacto- N-neotetraose (LNnT), disialyllacto-N-tetraose (DSLNT), lacto-N-fucopentaose I (LNFPI), 6’- sialyllactose (6SL) and 2-fucosyllactose (2FL); or a combination thereof; optionally wherein the HMO is LNnT and/or 6SL.
  • LNT lacto-N-tetraose
  • LNnT lacto- N-neotetraose
  • DSLNT disialyllacto-N-tetraose
  • LNFPI lacto-N-fucopentaose I
  • 6SL sialyllactose
  • 2FL 2-fucosyllactose
  • the invention also provides a postbiotic composition for improving the gut health of a subject, the composition comprising: (a) at least one inanimate Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificunr, and/or
  • Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum.
  • the postbiotic composition may comprise:
  • Clostridium perfringens at least two inanimate Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum', and/or
  • Clostridium perfringens metabolites from at least two Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum.
  • the postbiotic composition may comprise:
  • Clostridium perfringens at least three inanimate Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum', and/or
  • Clostridium perfringens metabolites from at least three Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum.
  • the probiotic composition or postbiotic composition may comprise: a) a Clostridium perfringens species selected from the group consisting of: Clostridium perfringens strain AM1 (deposited under NCTC accession number 24022903), Clostridium perfringens strain JC26 (deposited under NCTC accession number 24022904), Clostridium perfringens strain AM248 (deposited under NCTC accession number 24022906), Clostridium perfringens strain JC36 (deposited under NCTC accession number 24022907), Clostridium perfringens strain JC33 (deposited under NCTC accession number 24022912), Clostridium perfringens strain AM226 (deposited under NCTC accession number 24022913), and Clostridium perfringens strain JC29 (deposited under NCTC accession number 24022914); and/or b) the Clostridium baratti strain AM37 (deposited under NCTC accession number 24022908); and/or c)
  • the probiotic composition or postbiotic composition may be in the form of a liquid medium, gel medium, powder, dissolvable medium, chewable medium, or any other ingestible medium.
  • the probiotic composition or postbiotic composition may be a milk product.
  • the probiotic composition or postbiotic composition may be an infant formula, a starter infant formula, a follow-on or follow-up infant formula, a baby food, or an infant cereal composition.
  • the probiotic composition or postbiotic composition may be a powder, a liquid or a solid.
  • the invention also provides a probiotic composition or postbiotic composition of the invention for use in improving the gut microbiome and/or the gut health of a subject.
  • the subject may be an infant.
  • the infant may be a neonate, a preterm infant, an infant small for gestational age, or an infant born by C-section.
  • the infant may be hospitalised and/or is undergoing antibiotic treatment.
  • the composition reduces pathogen overgrowth in the gut, promotes gut development, promotes gut maturation, promotes immunity, decreases gut inflammation, and/or promotes enteral feeding tolerance in the subject.
  • the invention also provides a probiotic composition or postbiotic composition of the invention for use in preventing or treating a gastrointestinal disorder, an allergy, nappy rash, colic, or a symptom thereof, in a subject.
  • the invention also provides a probiotic composition for use in preventing or treating a gastrointestinal disorder, an allergy, nappy rash, colic, or a symptom thereof, in a subject; wherein the probiotic composition comprises at least one Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum; and the subject consumes at least one prebiotic prior, after, or during administration of the probiotic composition, wherein the prebiotic is a mammalian milk oligosaccharide (MMO), a precursor and/or a derivative thereof.
  • MMO mammalian milk oligosaccharide
  • the invention also provides a probiotic composition for use in preventing or treating a gastrointestinal disorder, an allergy, nappy rash, colic, or a symptom thereof, in a subject that consumes at least one prebiotic prior, after, or during administration of the probiotic composition; wherein the probiotic composition comprises at least one Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum; and wherein the prebiotic is a mammalian milk oligosaccharide (MMO), a precursor and/or a derivative thereof.
  • MMO mammalian milk oligosaccharide
  • the invention also provides a method of treating or preventing a gastrointestinal disorder, an allergy, nappy rash, colic, or a symptom thereof in a subject, comprising administering a therapeutically effective amount of the probiotic composition or the postbiotic composition of the invention to said subject.
  • the invention also provides a method of treating or preventing a gastrointestinal disorder, an allergy, nappy rash, colic, or a symptom thereof in a subject, comprising administering a therapeutically effective amount of a probiotic composition prior, after, or during administration of a prebiotic composition, wherein the probiotic composition comprises at least one Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum; and wherein the prebiotic is a mammalian milk oligosaccharide (MMO), a precursor and/or a derivative thereof.
  • MMO mammalian milk oligosaccharide
  • the gastrointestinal disorder may affect the integrity of the intestinal lining.
  • the gastrointestinal disorder may be selected from the group consisting of: intestinal inflammation, irritable bowel syndrome, colitis, necrotising enterocolitis, late onset sepsis, focal intestinal perforation, and inflammatory bowel disease.
  • the gastrointestinal disorder may be necrotising enterocolitis.
  • the subject may be an infant.
  • the infant may be a neonate, a preterm infant, an infant small for gestational age, or an infant born by C-section.
  • the infant may be hospitalised and/or is undergoing antibiotic treatment.
  • the invention also provides a probiotic composition for improving the gut microbiome and/or gut health of a subject, the composition comprising at least one Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificunr, wherein a) the Clostridium perfringens species is selected from the group consisting of:
  • Clostridium perfringens strain AM248 (deposited under NCTC accession number 24022906)
  • Clostridium perfringens strain JC36 (deposited under NCTC accession number 24022907)
  • Clostridium perfringens strain AM226 (deposited under NCTC accession number 24022913), and Clostridium perfringens strain JC29 (deposited under NCTC accession number 24022914); and/or b) the Clostridium baratti species is Clostridium baratti strain AM37 (deposited under NCTC accession number 24022908); and/or c) the Clostridium tertium species is selected from the group consisting of: Clostridium tertium strain JC25 (deposited under NCTC accession number 24022905) and Clostridium tertium strain TB43 (deposited under NCTC accession number 24022911); and/or d) the Clostridium paraputrificum species is selected from the group consisting of: Clostridium paraputrificum strain JC53 (deposited under NCTC accession number 24022902) and Clostridium paraputrificum strain JC66 (deposited under NCTC accession number 24022910).
  • the invention also provides the use of Clostridium perfringens, Clostridium baratii, Clostridium tertium and/or Clostridium paraputrificum as a probiotic or postbiotic.
  • the invention also provides Clostridium perfringens, Clostridium baratii, Clostridium tertium and/or Clostridium paraputrificum, or a Clostridium postbiotic thereof, for use in improving the gut microbiome and/or gut health in a subject
  • the invention also provides a bacterial strain selected from the group consisting of: Clostridium paraputrificum strain JC53 (deposited under NCTC accession number 24022902), Clostridium perfringens strain AM1 (deposited under NCTC accession number 24022903), Clostridium perfringens strain JC26 (deposited under NCTC accession number 24022904), Clostridium tertium strain JC25 (deposited under NCTC accession number 24022905), Clostridium perfringens strain AM248 (deposited under NCTC accession number 24022906), Clostridium perfringens strain JC36 (deposited under NCTC accession number 24022907), Clostridium baratti strain AM37 (deposited under NCTC accession number 24022908), Clostridium butyricum strain JC31 (deposited under NCTC accession number 24022909), Clostridium paraputrificum strain JC66 (deposited under NCTC accession number 24022910), Clostridium tertium strain
  • Figure 1 shows that several species of Clostridium and Bifidobacterium can use a range of HMOs.
  • White squares containing “NA” in the DSLNT row indicate these co-cultures were not performed due to limited availability of DSLNT.
  • Figure 1 B contains additional Clostridium species (Clostridium paraputrificum) that can use HMOs and is normalised to glucose.
  • Figure 2 shows Clostridium perfringens is the most abundant Clostridium species in early life and is higher in healthy infants compared to infants diagnosed with necrotising enterocolitis during the critical window of NEC risk.
  • DOL day of life.
  • Figure 4 shows Clostridium perfringens is higher in healthy infants (NoNEC) compared to infants before they were diagnosed with necrotising enterocolitis (PreNEC), but not after recovery from NEC (PostNEC).
  • Figure 5 shows the postbiotic (i.e. , conditioned medium) from the growth of Clostridium perfringens on HMOs was inhibitory to a range of pathobionts (E. coli, E. faecalis, K. oxytoca, K. pneumoniae, E. cloacae and E. faecium).
  • Figure 6 shows the postbiotic (i.e., conditioned medium) from the growth of Clostridium tertium on HMOs was inhibitory to a range of pathobionts (E. coli, E. faecium, K. oxytoca, K. pneumoniae, E. cloacae, E. faecalis and S. haemolyticus).
  • Figure 8 shows the postbiotic (i.e., conditioned medium) from the growth of Clostridium tertium on HMOs promoted the growth of a range of beneficial Bifidobacterium spp. (B. bifidum, B. breve and B. iongum). It also shows the postbiotic inhibited the growth of an adult-derived strain of B. infantis.
  • conditioned medium i.e., conditioned medium
  • Figure 9 shows that live Clostridium perfringens does not negatively impact the growth of B. infantis when the two species are cultured together.
  • Figure 11 shows the postbiotic from the growth of Clostridium perfringens on HMOs exerted protective effects on a human neonatal intestinal organoid monolayer.
  • A Monolayer integrity, as measured by trans-epithelial resistance (TEER), was increased by the postbiotic post-treatment. The postbiotic also inhibited secretion of pro-inflammatory cytokines: IL8 apically (B) and basolaterally (C); CCL2 apically (D) and basolaterally (E); CCL7 apically (F) and basolaterally (G); TNFa apically (H) and basolaterally (I); CXCL5 basolaterally (J). Letters at the top of the plot indicate outcomes of Tukey’s statistical test. Conditions with the same letters are not significantly different from one another.
  • Figure 12 shows the postbiotic from the growth of B. infantis on HMOs exerted similar, but weaker effects (compared to Clostridium perfringens (Figure 11)) on a human neonatal intestinal organoid monolayer. Panels appear in the same order as Figure 11.
  • A Monolayer integrity, as measured by trans-epithelial resistance (TEER), was increased by the postbiotic post-treatment.
  • the B. infantis postbiotic failed to inhibit apical secretion of pro-inflammatory IL8 (B), CCL7 (F), TNFa (H) and basolateral secretion of CXCL5 (J).
  • Figure 13 A-G shows that when growing on HMOs, Clostridium spp. produce a greater quantity of the SCFAs propionate, butyrate, valerate and hexanoate than Bifidobacterium spp., while Bifidobacterium spp. produced greater acetate.
  • H and I further show that the global profile of Clostridium-produced SCFAs is distinct from that of Bifidobacterium- produced SCFAs, with Clostridium samples clustering separately from Bifidobacterium samples in both unsupervised ordination and dendrogram analyses.
  • the ordination in H also emphasises that the SCFA profiles of Clostridium spp. grown on HMOs are more diverse than those of Bifidobacterium spp., with a far wider spread of Clostridium samples based on the SCFA profiles.
  • Figure 14 shows PCA ordination and dendrogram plots of untargeted metabolomics data performed on glucose and HMO postbiotics, derived from both Clostridium and Bifidobacterium. Both plots show that samples largely cluster separately based on genera, indicating that Clostridium postbiotics contain a metabolite profile that is largely distinct from that of Bifidobacterium.
  • FIG 16 shows that various of the Clostridium postbiotics contained polyamines, diamines and their precursors. For many of these compounds (ornithine, citrulline, spermidine, agmatine, putrescine), Clostridium postbiotics contained equivalent or greater quantities than were measured in Bifidobacterium postbiotics.
  • FIG. 18 shows that Clostridium postbiotics contained the neurotransmitters 3- hydroxy butyrate (A) and trimethylamine N-oxide (B). Both compounds were at higher quantities in some specific Clostridium postbiotics than were detected in the Bifidobacterium postbiotics.
  • the present invention relates to a probiotic composition for improving the gut microbiome and/or gut health of a subject, the composition comprising at least one Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum.
  • Clostridium species Clostridium perfringens, Clostridium baratii and Clostridium tertium and Clostridium paraputrificum are able to use a wide variety of HMOs as a carbon source.
  • HMOs Clostridium perfringens
  • Clostridium baratii and Clostridium tertium and Clostridium paraputrificum are able to use a wide variety of HMOs as a carbon source.
  • HMOs Clostridium species Clostridium perfringens, Clostridium baratii and Clostridium tertium and Clostridium paraputrificum
  • probiotic composition refers to a composition comprising live bacteria that are beneficial to the overall health of an individual (referred to as a subject herein) that consumes the composition.
  • Probiotic compositions are well known in the art.
  • Probiotic compositions that are described herein impart their beneficial effects in the gut of the subject, and therefore improve the gut microbiome and/or gut health of the subject.
  • Probiotic compositions may also be described as compositions that are utilised as a dietary supplement to alter the digestive tract microbiota of a subject in a beneficial manner without causing disease.
  • a probiotic composition comprises sufficient quantities of the live bacteria to impart the required beneficial effect on the subject.
  • the amount of bacteria in the probiotic composition may be referred to as a therapeutically effective amount.
  • Appropriate amounts of live bacteria can readily be identified by a person skilled in the art. Further details and examples are provided elsewhere herein.
  • Clostridium species The probiotic potential of Clostridium species has been identified previously (see for example, Guo et al., 2020 (Journal of animal science and biotechnology); and Cartman, Future Microbiol. (2011), 6(9), 969-971). Although several Clostridium strains are considered to be pathogenic, Clostridium species account for 10-40% of the total bacteria in the human gut and are predominantly commensal in nature.
  • the probiotic compositions provided herein comprise live bacteria from at least one Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium or Clostridium paraputrificum.
  • the probiotic compositions provided herein may comprise live bacteria from at least two Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium or Clostridium paraputrificum.
  • the probiotic composition may comprise live Clostridium perfringens and Clostridium baratii.
  • the probiotic composition may comprise live Clostridium perfringens and Clostridium tertium.
  • the probiotic composition may comprise live Clostridium perfringens and Clostridium paraputrificum.
  • the probiotic composition may comprise live Clostridium baratii and Clostridium paraputrificum.
  • the probiotic composition may comprise live Clostridium tertium and Clostridium paraputrificum.
  • the probiotic composition may comprise live Clostridium baratii and Clostridium tertium.
  • the probiotic compositions provided herein may comprise live bacteria from at least three Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium or Clostridium paraputrificum.
  • the probiotic composition may comprise live Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum.
  • Clostridium (Clostridiaceae) is a genus of rod-shaped, anaerobic, chemoorganotrophic (ability to ferment), and spore-forming bacteria belonging to the Bacillaceae family of the phylum Firmicutes.
  • Non-limiting examples of Clostridium species include Clostridium perfringens, Clostridium baratii, Clostridium tertium, Clostridium paraputrificum, Clostridium butyricum, Clostridium botulinum, Clostridium sporogenes, Clostridium difficile, Clostridium tetani, and Clostridium ramosum.
  • Species of Clostridium are ubiquitous; naturally colonising the environmental medium (e.g.
  • Clostridium species are a well-understood regulator of intestinal homeostasis. Clostridium species are Gram-variable, as they generally stain Gram-positive, however, as the culture ages, an increase in Gram-negative cells is often observable. Methods for performing a Gram stain are well known in the art.
  • Clostridium species primarily exist in three states: vegetative, spore-forming, and as an endospore. Clostridium species in either the vegetative or spore-forming states are considered “live” herein, as they are able to grow and reproduce.
  • the term ‘spore-forming’ as used herein is intended to refer to Clostridium species at any stage of the sporulation cycle, except free endospore.
  • the terms “spore(s)” and “endospore(s)” as used herein are interchangeable and refer to a dormant, tough, and non-reproductive free structure produced by the Clostridium species.
  • Clostridium perfringens is an obligate anaerobe, and is categorised into non-pathogenic and pathogenic strains, with the latter comprising seven types: A, B, C, D, E, F, and G.
  • Non- pathogenic Clostridium perfringens strains comprise Clostridium perfringens strain SM101 and type A, and these are capable of producing secondary bile acids.
  • Pathogenic Clostridium perfringens strains are frequently responsible for food poisoning and a large proportion gas gangrene cases.
  • the probiotic compositions described herein that comprise live Clostridium perfringens are beneficial to the overall health of an individual (referred to as a subject herein) that consumes the composition.
  • the probiotic compositions described herein that comprise live Clostridium perfringens impart their beneficial effects in the gut of the subject, and therefore improve the gut microbiome of the subject.
  • the probiotic compositions described herein that comprise live Clostridium perfringens may be utilised as a dietary supplement to alter the digestive tract microbiota of a subject in a beneficial manner without causing disease.
  • the Clostridium perfringens is therefore a non-pathogenic strain, such as Clostridium perfringens strain SM101 and type A.
  • Clostridium perfringens strains have been characterised and the presence or absence of toxin expression and/or antimicrobial resistance (AMR) in these strains has been studied previously (see for example, Kiu et al., Dissemination and pathogenesis of toxigenic Clostridium perfringens strains linked to neonatal intensive care units and Necrotising Enterocolitis; 2021 bioRxiv preprint doi: https://doi.org/10.1101/2021.08.03.454877). A person of skill in the art can therefore readily identify non-pathogenic strains of Clostridium perfringens.
  • Clostridium perfringens provided herein is pfoA-negative. In other words, they do not express the pore-forming toxin perfringolysin O; PFO, which has been heavily associated with the pathogenesis of myonecrosis (gas gangrene).
  • Clostridium perfringens provided herein is a cpb2-negative. In other words, they do not express beta2-toxin, CPB2, which has been associated with virulence.
  • Clostridium perfringens provided herein does not comprise the plasmid pCW3 and/or pCP13, which have long been recognised as key mobile genetic elements for transfer of virulence genes, including toxins.
  • Clostridium perfringens provided herein is negative for one or more of the following toxin-associated genes: cpe, iap, ibp becA, becB and/or edpA.
  • the toxin genes pfoA, cpe, iap, ibp becA, becB and/or edpA are well known. For more details see for example Kiu et al., 2021 , referenced above.
  • the Clostridium perfringens provided herein is negative for one or more antimicrobial resistance genes selected from the group consisting of: cfrC, ET-Tu, gyrA, gryB, rpoC, and TetA. For example it may be negative for each of them (i.e.
  • Clostridium perfringens provided herein is negative for rpoB.
  • Clostridium baratii is an obligate anaerobe, and is rarely associated with human disease, however, when it is, it will usually occur after eating food contaminated with vegetative Clostridium baratii or its spores. Clostridium baratii can produce toxins which cause botulism, and is a rare cause of infant botulism.
  • the probiotic compositions described herein that comprise live Clostridium baratii are beneficial to the overall health of an individual (referred to as a subject herein) that consumes the composition.
  • the probiotic compositions described herein that comprise live Clostridium baratii impart their beneficial effects in the gut of the subject, and therefore improve the gut microbiome of the subject.
  • the probiotic compositions described herein that comprise live Clostridium baratii may be utilised as a dietary supplement to alter the digestive tract microbiota of a subject in a beneficial manner without causing disease. In one example, the Clostridium baratii is therefore a non-pathogenic strain.
  • Clostridium baratii strains have been characterised and the presence or absence of toxin expression and/or antimicrobial resistance (AMR) of these strains has been studied previously - see for example Silva-Andrade et al., Microorganisms. 2022 Feb; 10(2): 213. A person of skill in the art can therefore readily identify non-pathogenic strains of Clostridium baratii.
  • the Clostridium baratii provided herein is negative for one or more toxin genes selected from the group consisting of: boNT, colA, NagH, Nagi, NagJ, NagK, NagL, nanH, nanl, nanJ, tetX, and pfoA.
  • boNT colA
  • NagH Nagi
  • NagJ NagK
  • NagL NagL
  • nanH nanl
  • nanJ nanJ
  • tetX pfoA
  • the Clostridium baratii provided herein is negative for pic (alpha toxin phospholipase C).
  • NanH, nanl, and nanJ genes express sialidases.
  • pfoA expresses theta-toxin/perfringolysin O.
  • NagH, Nagi, NagJ, nagK and NagL genes express mu-toxins, and colA expresses microbial collagenase.
  • BoNT genes express botulinum toxins and tetX genes express tetanus toxin. For more information see for example Silva-Andrade et al., Microorganisms.
  • the Clostridium baratii provided herein is negative for one or more antimicrobial resistance genes selected from the group consisting of: cfrC, ET-Tu, gyrA, gryB, rpoC, and TetA. For example it may be negative for each of them (i.e. negative for all of the following): cfrC, ET-Tu, gyrA, gryB, rpoC, and TetA. In some examples, the Clostridium baratii provided herein is negative for rpoB.
  • antimicrobial genes cfrC, ET-Tu, gyrA, gryB, rpoC, TetA and rpoB are well characterised. For more details see for example Silva-Andrade et al., Microorganisms. 2022 Feb; 10(2): 213.
  • Clostridium tertium is both anaerobic and aerotolerant. Although the normal habitat of Clostridium tertium is the soil, it is commonly found as a commensal colonising the digestive tract of humans and animals. Although rarely pathogenic, it is thought to be associated with enterocolitis in preterm neonates.
  • the probiotic compositions described herein that comprise live Clostridium tertium are beneficial to the overall health of an individual (referred to as a subject herein) that consumes the composition.
  • the probiotic compositions described herein that comprise live Clostridium tertium impart their beneficial effects in the gut of the subject, and therefore improve the gut microbiome of the subject.
  • the probiotic compositions described herein that comprise live Clostridium tertium may be utilised as a dietary supplement to alter the digestive tract microbiota of a subject in a beneficial manner without causing disease.
  • the Clostridium tertium is therefore a non-pathogenic strain.
  • Clostridium tertium strains have been characterised and the presence or absence of toxin expression and/or antimicrobial resistance (AMR) of these strains has been studied previously. A person of skill in the art can therefore readily identify non-pathogenic strains of Clostridium tertium.
  • the Clostridium tertium provided herein is negative for one or more antimicrobial resistance genes selected from the group consisting of: cfrC, ET-Tu, gyrA, gryB, rpoC, and TetA. For example it may be negative for each of them (i.e. negative for all of the following): cfrC, ET-Tu, gyrA, gryB, rpoC, and TetA. In some examples, the Clostridium tertium provided herein is negative for rpoB.
  • Clostridium paraputrificum is a anaerobic, motile, gram-positive bacterium that is considered part of the normal intestinal microbiome. It is rarely associated with human disease but has been reported in bacteremia.
  • the probiotic compositions described herein that comprise live Clostridium paraputrificum are beneficial to the overall health of an individual (referred to as a subject herein) that consumes the composition.
  • the probiotic compositions described herein that comprise live Clostridium paraputrificum impart their beneficial effects in the gut of the subject, and therefore improve the gut microbiome of the subject.
  • the probiotic compositions described herein that comprise live Clostridium paraputrificum may be utilised as a dietary supplement to alter the digestive tract microbiota of a subject in a beneficial manner without causing disease.
  • the Clostridium paraputrificum is therefore a non-pathogenic strain.
  • Clostridium paraputrificum strains have been characterised and the presence or absence of toxin expression and/or antimicrobial resistance (AMR) of these strains has been studied previously. A person of skill in the art can therefore readily identify non-pathogenic strains of Clostridium paraputrificum.
  • the Clostridium paraputrificum provided herein is negative for one or more antimicrobial resistance genes selected from the group consisting of: cfrC, ET-Tu, gyrA, gryB, rpoC, and TetA. For example it may be negative for each of them (i.e. negative for all of the following): cfrC, ET-Tu, gyrA, gryB, rpoC, and TetA. In some examples, the Clostridium paraputrificum provided herein is negative for rpoB.
  • Clostridium paraputrificum strain JC53 (24022902), Clostridium perfringens strain AM1 (24022903), Clostridium perfringens strain JC26 (24022904), Clostridium tertium strain JC25 (24022905), Clostridium perfringens strain AM248 (24022906), Clostridium perfringens strain JC36 (24022907), Clostridium baratti strain AM37 (24022908), Clostridium butyricum strain JC31 (24022909), Clostridium paraputrificum strain JC66 (24022910), Clostridium tertium strain TB43 (24022911), Clostridium perfringens strain JC33 (24022912), Clostridium perfringens strain AM226 (24022913), and Clostridium perfringens strain JC29 (24022914) have been found to be particularly important in the context of the present invention.
  • Clostridium paraputrificum strain deposited under NCTC accession number 24022902 may be referred to herein as “JC53” or “strain JC53”.
  • Clostridium paraputrificum strain JC53 (deposited under NCTC accession number 24022902) was deposited at Culture Collections, UK Health Security Agency (Porton Down, Salisbury, SP40JG, UK). This strain was deposited under The Budapest Treaty of 1977 on 29 February 2024.
  • a Clostridium perfringens strain deposited under NCTC accession number 24022903 may be referred to herein as “AM1” or “strain AM1”.
  • Clostridium perfringens strain AM1 (deposited under NCTC accession number 24022903) was deposited at Culture Collections, UK Health Security Agency (Porton Down, Salisbury, SP4 0JG, UK). This strain was deposited under The Budapest Treaty of 1977 on 29 February 2024.
  • Clostridium perfringens strain deposited under NCTC accession number 24022904 may be referred to herein as “JC26” or “strain JC26”.
  • Clostridium perfringens strain JC26 (deposited under NCTC accession number 24022904) was deposited at Culture Collections, UK Health Security Agency (Porton Down, Salisbury, SP4 OJG, UK). This strain was deposited under The Budapest Treaty of 1977 on 29 February 2024.
  • a Clostridium tertium strain deposited under NCTC accession number 24022905 may be referred to herein as “JC25” or “strain JC25”.
  • Clostridium tertium strain JC25 (deposited under NCTC accession number 24022905) was deposited at Culture Collections, UK Health Security Agency (Porton Down, Salisbury, SP4 OJG, UK). This strain was deposited under The Budapest Treaty of 1977 on 29 February 2024.
  • a Clostridium perfringens strain deposited under NCTC accession number 24022906 may be referred to herein as “AM248” or “strain AM248”.
  • Clostridium perfringens strain AM248 (deposited under NCTC accession number 24022906) was deposited at Culture Collections, UK Health Security Agency (Porton Down, Salisbury, SP4 OJG, UK). This strain was deposited under The Budapest Treaty of 1977 on 29 February 2024.
  • Clostridium perfringens strain deposited under NCTC accession number 24022907 may be referred to herein as “JC36” or “strain JC36”.
  • Clostridium perfringens strain JC36 (deposited under NCTC accession number 24022907) was deposited at Culture Collections, UK Health Security Agency (Porton Down, Salisbury, SP4 OJG, UK). This strain was deposited under The Budapest Treaty of 1977 on 29 February 2024.
  • a Clostridium baratti strain deposited under NCTC accession number 24022908 may be referred to herein as “AM37” or “strain AM37”.
  • Clostridium baratti strain AM37 (deposited under NCTC accession number 24022908) was deposited at Culture Collections, UK Health Security Agency (Porton Down, Salisbury, SP4 OJG, UK). This strain was deposited under The Budapest Treaty of 1977 on 29 February 2024.
  • Clostridium butyricum strain deposited under NCTC accession number 24022909 may be referred to herein as “JC31” or “strain JC31”.
  • Clostridium butyricum strain JC31 (deposited under NCTC accession number 24022909) was deposited at Culture Collections, UK Health Security Agency (Porton Down, Salisbury, SP4 OJG, UK). This strain was deposited under The Budapest Treaty of 1977 on 29 February 2024.
  • a Clostridium paraputrificum strain deposited under NCTC accession number 24022910 may be referred to herein as “JC66” or “strain JC66”.
  • Clostridium paraputrificum strain JC66 (deposited under NCTC accession number 24022910) was deposited at Culture Collections, UK Health Security Agency (Porton Down, Salisbury, SP4 OJG, UK). This strain was deposited under The Budapest Treaty of 1977 on 29 February 2024.
  • a Clostridium tertium strain deposited under NCTC accession number 24022911 may be referred to herein as “TB43” or “strain TB43”.
  • Clostridium tertium strain TB43 (deposited under NCTC accession number 24022911) was deposited at Culture Collections, UK Health Security Agency (Porton Down, Salisbury, SP4 OJG, UK). This strain was deposited under The Budapest Treaty of 1977 on 29 February 2024.
  • Clostridium perfringens strain deposited under NCTC accession number 24022912 may be referred to herein as “JC33” or “strain JC33”.
  • Clostridium perfringens strain JC33 (deposited under NCTC accession number 24022912) was deposited at Culture Collections, UK Health Security Agency (Porton Down, Salisbury, SP4 OJG, UK). This strain was deposited under The Budapest Treaty of 1977 on 29 February 2024.
  • a Clostridium perfringens strain deposited under NCTC accession number 24022913 may be referred to herein as “AM226” or “strain AM226”.
  • Clostridium perfringens strain AM226 (deposited under NCTC accession number 24022913) was deposited at Culture Collections, UK Health Security Agency (Porton Down, Salisbury, SP4 OJG, UK). This strain was deposited under The Budapest Treaty of 1977 on 29 February 2024.
  • Clostridium perfringens strain deposited under NCTC accession number 24022914 may be referred to herein as “JC29” or “strain JC29”.
  • Clostridium perfringens strain JC29 (deposited under NCTC accession number 24022914) was deposited at Culture Collections, UK Health Security Agency (Porton Down, Salisbury, SP4 OJG, UK). This strain was deposited under The Budapest Treaty of 1977 on 29 February 2024.
  • Clostridium paraputrificum species may be selected from the group consisting of: Clostridium paraputrificum strain JC53 (24022902) and Clostridium paraputrificum strain JC66 (24022910).
  • Clostridium perfringens species may be selected from the group consisting of: Clostridium perfringens strain AM1 (24022903), Clostridium perfringens strain JC26 (24022904), Clostridium perfringens strain AM248 (24022906), Clostridium perfringens strain JC36 (24022907), Clostridium perfringens strain JC33 (24022912), Clostridium perfringens strain AM226 (24022913), and Clostridium perfringens strain JC29 (24022914).
  • Clostridium tertium species may be selected from the group consisting of: Clostridium tertium strain JC25 (24022905) and Clostridium tertium strain TB43 (24022911).
  • Clostridium baratti species may be Clostridium baratti strain AM37 (24022908).
  • Clostridium butyricum species may be Clostridium butyricum strain JC31 (24022909).
  • Probiotic bacteria may be combined with a prebiotic. They can be combined into a single composition that comprises both the probiotic bacteria and at least one prebiotic such that they are consumed simultaneously by the subject (in other words, a probiotic composition provided herein may further comprise a prebiotic as well). Alternatively, they may be in separate (distinct) compositions, whereby the probiotic composition of the invention and a prebiotic composition are consumed separately (simultaneously or consecutively) by the subject.
  • At least one prebiotic is present within the probiotic composition.
  • at least one prebiotic is provided as a separate prebiotic composition (separate from the probiotic composition) and is administered to the subject either prior, after, or during administration of the probiotic composition. Examples of such prebiotic compositions are described elsewhere herein.
  • a probiotic composition is therefore provided, wherein the probiotic bacteria are combined with at least one prebiotic within the same composition.
  • Such compositions may also be referred to herein as a “synbiotic” composition.
  • a prebiotic composition is also provided, which lacks the probiotic bacteria described herein (i.e. lacks Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum), wherein the prebiotic composition is for separate (simultaneous or consecutive) administration to the same subject as the probiotic composition of the invention. Details of the prebiotic composition are provided elsewhere herein.
  • prebiotic refers to a component that promotes the growth of probiotic bacteria.
  • prebiotic may refer to food ingredients or bacterially produced substances that are not readily digestible by endogenous host enzymes (in other words, the prebiotic is not digestible by the subject that consumes the composition of the invention, but rather by the probiotic bacteria that may colonise its gut).
  • Prebiotics may originate from several sources, such as artichokes, asparagus, bananas, berries, tomatoes, garlic, onions, legumes, green vegetables, wholegrain cereals, and milk, such as breast milk or cows’ milk.
  • Prebiotics may for example be MMOs (mammalian milk oligosaccharides) such as HMOs (human milk oligosaccharides).
  • prebiotics may be synthetic in origin or manufactured artificially.
  • Clostridium species are able to ferment several nutrients including, but not limited to, protein, carbohydrate, organic acid, and non-digestible substrates (such as oligosaccharides), to generate short-chain fatty acids (SCFAs) such as propionic acid, butyric acid, acetic acid, and solvents such as acetone and butanol.
  • SCFAs short-chain fatty acids
  • Clostridium species Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum are able to use a wide variety of prebiotics, in particular MMOs such as HMOs.
  • MMOs such as HMOs.
  • IVA indolelactic acid
  • the probiotic composition of the invention comprises at least one prebiotic. In one example it comprises at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen etc prebiotics.
  • the prebiotic is a mammalian milk oligosaccharide (MMO), a precursor and/or a derivative thereof.
  • MMO mammalian milk oligosaccharide
  • MMO refers to indigestible glycans, sometimes referred to as “dietary fiber”, or carbohydrate polymers found in mammalian milk which are not metabolized by any combination of mammalian digestive enzymes.
  • Mammalian milk contains a significant quantity of MMO that is not usable directly as an energy source for the milk-fed mammal but may be usable by many of the microorganisms in the gut of that mammal.
  • MMOs can be found as free oligosaccharides (3 sugar units or longer, e.g., 3-20 sugar residues) or they may be conjugated to proteins or lipids.
  • MMO mammalian milk oligosaccharides
  • the MMO can include one or more of fucosyllactose, lacto-N-fucopentose, lactodifucotetrose, sialyllactose, disialyllacto-N-tetraose, 2'-fucosyllactose, 3'-sialyllactoseamin, 3'- fucosyllactose, 3'-sialyl-3-fucosyllactose, 3'-sialyllactose, 6'-sialyllactosamine, 6'-sialyllactose, difucosyllactose, lacto-N-fucosylpentose I, lacto-N-fucosylpentose II, lacto-N-fucosylpentose III, lacto-N-fucosylpentose V, sialyllacto-N-tetraose, or derivatives thereof.
  • MMOs are well known in the art, including that from human milk (HMO), bovine milk (BMO), ovine milk (OMO), equine milk (EMO) or caprine milk (CMO).
  • the oligosaccharides can be obtained from a process that involves cheese or yogurt production and can be from whey sources such as, but not limited to, the whey permeate, or a processed whey permeate, where the processing steps may include, but are not limited to, removal of lactose, removal of minerals, removal of peptides, and removal of monosaccharides, but which in any case, results in the concentration of the MMO to levels that are greater than 20%, greater than 30%, greater than 40%, greater than 50%, greater than 60%, greater than 70%, or greater than 80% of the total dry matter of the product.
  • the probiotic composition of the invention comprises at least one MMO.
  • a prebiotic composition comprising at least one MMO is administered to the subject as a separate (distinct) composition to the probiotic composition of the invention, whereby the probiotic composition of the invention and a prebiotic composition are consumed separately (simultaneously or consecutively) by the subject.
  • the prebiotic composition comprising at least one MMO may be a milk selected from the group consisting of human milk (HMO), bovine milk (BMO), ovine milk (OMO), equine milk (EMO) or caprine milk (CMO).
  • the prebiotic is a human milk oligosaccharide (HMO), a precursor and/or a derivative thereof.
  • HMO human milk oligosaccharide
  • HMOs are a complex mixture of more than 200 non-digestible and non-nutritional carbohydrate polymers, which are not metabolised by any combination of human digestive enzymes in the digestive tract. These HMOs occur naturally in human breast milk only. As they are non-digestible, the subject is unable to utilise them as an energy source. However, HMOs are a bonafide energy source for several probiotic members of the gut microbiota in the subject. After lactose and lipids, HMOs are the third most abundant component of breast milk.
  • HMOs Human breast milk contains three major HMO types: fucosylated HMOs, sialylated HMOs, and nonfucosylated neutral HMOs, which typically make up 35-50%, 12-14%, and 42- 55% of the total HMO content of milk, respectively.
  • HMOs are made of five basic monosaccharides: D-glucose, D-galactose, N-acetylglucosamine, L-fucose, and /V- Acetylneuraminic acid (sialic acid).
  • the majority of HMOs are based on a lactose molecule at the reducing end, and branching can be linear or branched through beta (1-3) or beta (1-6) bonds.
  • Non-limiting examples of exemplary HMOs include lacto-N-tetraose (LNT), lacto-N- neotetraose (LNnT), disialyllacto-N-tetraose (DSLNT), lacto-N-fucopentaose I (LNFPI), 6’- sialyllactose (6SL), and 2-fucosyllactose (2FL).
  • LNT lacto-N-tetraose
  • LNnT lacto-N- neotetraose
  • DSLNT disialyllacto-N-tetraose
  • LNFPI lacto-N-fucopentaose I
  • 6SL 6’- sialyllactose
  • 2-fucosyllactose (2FL 2-fucosyllactose
  • the HMO used for promoting colonisation and/or growth of probiotic bacteria present in the probiotic compositions described herein can include fucosylated HMOs, precursors, or derivatives thereof.
  • the probiotic compositions provided herein may comprise, or may be administered in combination with, a fucosylated HMO, precursor or derivative thereof (prebiotic).
  • fucosylated HMOs include 2FL, LNFPI, and LDFH I which can be purified from human milk or produced directly from chemical synthesis. 2FL is the most abundant HMO, constituting nearly 30% of the total HMOs in human breast milk.
  • the HMO used for promoting colonisation and/or growth of the probiotic bacteria present in the probiotic compositions described herein can include sialylated HMOs, precursors or derivatives thereof.
  • the probiotic compositions provided herein may comprise, or may be administered in combination with, a sialylated HMO, precursor or derivative thereof (prebiotic).
  • sialylated HMO derivatives include DSLNT, 3SL, 6SL, LSTa, LSTb, LSTc.
  • the HMO used for promoting colonisation and/or growth of the probiotic bacteria present in the probiotic compositions described herein can include nonfucosylated neutral HMOs, precursors or derivatives thereof. Accordingly, the probiotic compositions provided herein may comprise, or may be administered in combination with, a nonfucosylated neutral HMO, precursor or derivative thereof (prebiotic).
  • nonfucosylated neutral HMOs include LNT, LNnT and LNnH.
  • the HMO that is present in the probiotic composition of the invention is selected from the group consisting of: lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), disialyllacto-N-tetraose (DSLNT), lacto-N-fucopentaose I (LNFPI), 6’-sialyllactose (6SL) and 2-fucosyllactose (2FL); or a combination thereof.
  • LNT lacto-N-tetraose
  • LNnT lacto-N-neotetraose
  • DSLNT disialyllacto-N-tetraose
  • LNFPI lacto-N-fucopentaose I
  • 6SL 6’-sialyllactose
  • 2FL 2-fucosyllactose
  • the HMO that is present in the probiotic composition of the invention is LNnT and/or 6SL.
  • the probiotic composition of the invention comprises at least one HMO.
  • a prebiotic composition comprising at least one HMO is administered to the subject as a separate (distinct) composition to the probiotic composition of the invention, whereby the probiotic composition of the invention and a prebiotic composition are consumed separately (simultaneously or consecutively) by the subject.
  • the abundance of specific HMOs in human milk is variable, and may change based on the genetics, diet, physiological state of the mother, pathological state of the mother, and/or psychological state of the mother.
  • the HMO composition received by the subject at a certain time point may reflect that of a healthy mother at the corresponding time point.
  • a plurality of HMOs are present within the probiotic composition of the invention.
  • the probiotic composition may comprise at least two, at least three, at least four, at least five, at least six etc HMOs.
  • the HMOs present in the probiotic composition of the invention may be a mixture of lacto-N- tetraose (LNT), lacto-N-neotetraose (LNnT), disialyllacto-N-tetraose (DSLNT), lacto-N- fucopentaose I (LNFPI), 6’-sialyllactose (6SL), and/or 2-fucosyllactose (2FL), which are all naturally found in human milk.
  • LNT lacto-N- tetraose
  • LNnT lacto-N-neotetraose
  • DSLNT disialyllacto-N-tetraose
  • LNFPI lacto-N- fucopentaose I
  • 6SL 6’-sialyllactose
  • 2FL 2-fucosyllactose
  • the probiotic composition of the invention comprises human milk.
  • human milk is administered to the subject as a separate (distinct) composition to the probiotic composition of the invention, whereby the probiotic composition of the invention and a prebiotic composition are consumed separately (simultaneously or consecutively) by the subject.
  • the probiotic composition of the invention comprises at least one HMO precursor.
  • HMO precursor refers to mono-, di- and trisaccharides that are the parts of HMOs, that is glucose, galactose, N-acetyl-glucosamine, fucose, sialic acid, lactose, lacto-N-biose (Gaipi-3GlcNAc), N-acetyl-lactosamine (Gaipi-4GlcNAc) and lacto-N- triose (GlcNAcpi-3Gaipi-4Glc).
  • Preferred HMO precursors are selected from the group consisting of fucose, sialic acid, lacto-N-biose, N-acetyl-lactosamine and lacto-N-triose.
  • the probiotic composition of the invention comprises at least one HMO precursor.
  • a prebiotic composition comprising at least one HMO precursor is administered to the subject as a separate (distinct) composition to the probiotic composition of the invention, whereby the probiotic composition of the invention and a prebiotic composition are consumed separately (simultaneously or consecutively) by the subject.
  • the probiotic composition of the invention comprises Clostridium perfringens and at least one prebiotic.
  • Clostridium perfringens and LNnT, 6SL, 2FL, DSLNT, LNFP-I and/or LNT are examples of Clostridium perfringens and at least one prebiotic.
  • the probiotic composition of the invention comprises Clostridium perfringens and LNnT, 6SL, 2FL, DSLNT, and/or LNT.
  • the probiotic composition of the invention comprises Clostridium perfringens and LNnT, 6SL, 2FL, and/or DSLNT.
  • the probiotic composition of the invention comprises Clostridium perfringens and LNnT, 6SL and/or DSLNT. In one example, the probiotic composition of the invention comprises Clostridium perfringens and LNnT and/or 6SL.
  • the probiotic composition of the invention comprises Clostridium perfringens and LNnT.
  • the probiotic composition of the invention comprises Clostridium perfringens and 6SL.
  • the probiotic composition of the invention comprises Clostridium baratii and at least one prebiotic.
  • Clostridium baratii and LNnT, and/or LNT are examples of prebiotics.
  • the probiotic composition of the invention comprises Clostridium baratii and LNnT.
  • the probiotic composition of the invention comprises Clostridium baratii and LNT.
  • the probiotic composition of the invention comprises Clostridium tertium and at least one prebiotic.
  • Clostridium tertium and LNnT, and/or LNT are examples of prebiotics.
  • the probiotic composition of the invention comprises Clostridium tertium and LNnT.
  • the probiotic composition of the invention comprises Clostridium tertium and LNT.
  • the probiotic composition of the invention comprises Clostridium paraputrificum and at least one prebiotic.
  • Clostridium paraputrificum and LNnT, and/or LNT are examples of prebiotics.
  • the probiotic composition of the invention comprises Clostridium paraputrificum and LNnT.
  • the probiotic composition of the invention comprises Clostridium paraputrificum and LNT.
  • the probiotic composition may comprise a two or more Clostridium species selected from the group consisting of Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum.
  • the probiotic composition may comprise two or more Clostridium species and at least one prebiotic.
  • it may comprise Clostridium perfringens and Clostridium baratii and at least one prebiotic selected from the group consisting of: LNnT, 6SL, 2FL, DSLNT, LNFP-I and/or LNT.
  • it may comprise Clostridium perfringens and Clostridium baratii and at least one prebiotic selected from LNnT, and/or LNT.
  • it may comprise Clostridium perfringens and Clostridium tertium and at least one prebiotic selected from the group consisting of: LNnT, 6SL, 2FL, DSLNT, LNFP-I and/or LNT.
  • it may comprise Clostridium perfringens and Clostridium tertium and at least one prebiotic selected from LNnT, and/or LNT.
  • it may comprise Clostridium tertium and Clostridium baratii and at least one prebiotic selected from the group consisting of: LNnT, 6SL, 2FL, DSLNT, LNFP-I and/or LNT.
  • it may comprise Clostridium tertium and Clostridium baratii and at least one prebiotic selected from LNnT, and/or LNT.
  • it may comprise Clostridium perfringens and Clostridium paraputrificum and at least one prebiotic selected from the group consisting of: LNnT, 6SL, 2FL, DSLNT, LNFP-I and/or LNT.
  • it may comprise Clostridium perfringens and Clostridium paraputrificum and at least one prebiotic selected from LNnT, and/or LNT.
  • it may comprise Clostridium tertium and Clostridium paraputrificum and at least one prebiotic selected from the group consisting of: LNnT, 6SL, 2FL, DSLNT, LNFP-I and/or LNT.
  • it may comprise Clostridium tertium and Clostridium paraputrificum and at least one prebiotic selected from LNnT, and/or LNT.
  • it may comprise Clostridium baratii and Clostridium paraputrificum and at least one prebiotic selected from the group consisting of: LNnT, 6SL, 2FL, DSLNT, LNFP-I and/or LNT.
  • it may comprise Clostridium baratii and Clostridium paraputrificum and at least one prebiotic selected from LNnT, and/or LNT.
  • it may comprise Clostridium perfringens, Clostridium tertium, Clostridium baratii and Clostridium paraputrificum and at least one prebiotic selected from the group consisting of: LNnT, 6SL, 2FL, DSLNT, LNFP-I and/or LNT.
  • it may comprise Clostridium perfringens, Clostridium tertium, Clostridium baratii and Clostridium paraputrificum and at least one prebiotic selected from LNnT, and/or LNT.
  • the probiotic composition may comprise additional bacteria, such as Bifidobacterium. Accordingly, the probiotic composition may comprise Bifidobacterium and one or more Clostridium species selected from the group consisting of Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum.
  • Prebiotic composition A prebiotic composition is also provided, which comprises at least one prebiotic and lacks the probiotic bacteria described herein (i.e. lacks Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum), wherein the prebiotic composition is for separate (simultaneous or consecutive) administration to the same subject as the probiotic composition of the invention.
  • prebiotics examples include prebiotics that may be included in the prebiotic composition.
  • the prebiotic composition comprises at least one prebiotic. In one example it comprises at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen etc prebiotics.
  • the prebiotic in the prebiotic composition, is a mammalian milk oligosaccharide (MMO), a precursor and/or a derivative thereof.
  • MMO mammalian milk oligosaccharide
  • HMO human milk oligosaccharide
  • the HMO may be a fucosylated HMO, precursor, or derivative thereof.
  • the HMO may be a sialylated HMO, precursor, or derivative thereof.
  • the HMO may be a nonfucosylated neutral HMO, precursor, or derivative thereof. Non-limiting examples of these HMOs are provided elsewhere herein.
  • the HMO that is present in the prebiotic composition is selected from the group consisting of: lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), disialyllacto-N- tetraose (DSLNT), lacto-N-fucopentaose I (LNFPI), 6’-sialyllactose (6SL) and 2-fucosyllactose (2FL); or a combination thereof.
  • LNT lacto-N-tetraose
  • LNnT lacto-N-neotetraose
  • DSLNT disialyllacto-N- tetraose
  • LNFPI lacto-N-fucopentaose I
  • 6SL 6’-sialyllactose
  • 2FL 2-fucosyllactose
  • the HMO that is present in the prebiotic composition is LNnT and/or 6SL.
  • a plurality of HMOs are present within the prebiotic composition of the invention.
  • the prebiotic composition may comprise at least two, at least three, at least four, at least five, at least six etc HMOs.
  • the HMOs present in the prebiotic composition may be a mixture of lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), disialyllacto-N-tetraose (DSLNT), lacto-N-fucopentaose I (LNFPI), 6’-sialyllactose (6SL), and/or 2-fucosyllactose (2FL), which are all naturally found in human milk.
  • the prebiotic composition comprises a milk selected from the group consisting of: human milk (HMO), bovine milk (BMO), ovine milk (OMO), equine milk (EMO) or caprine milk (CMO).
  • the prebiotic composition comprises human milk.
  • the prebiotic composition comprises at least one HMO precursor.
  • HMO precursors are provided elsewhere herein.
  • the invention also provides a postbiotic composition for improving the gut health of a subject, the composition comprising:
  • Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificunr, and/or
  • Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum.
  • the postbiotic composition may further comprise:
  • the postbiotic composition for improving the gut health of a subject may comprise:
  • postbiotic composition is a general term to refer to a preparation of inanimate probiotic bacteria and/or their component parts (e.g., cellular debris) and/or their metabolites, wherein the composition is beneficial to the overall health of an individual (referred to as a subject herein) that consumes it.
  • Postbiotic compositions are well known in the art. Postbiotic compositions that are described herein impart their beneficial effects in the gut of the subject, and therefore improve the gut microbiome of the subject. Postbiotic compositions may also be described as compositions that are utilised as a dietary supplement to alter the digestive tract microbiota of a subject in a beneficial manner without causing disease.
  • a postbiotic composition comprises sufficient quantities of the inanimate probiotic bacteria (and/or their component parts (e.g., cellular debris) and/or their metabolites) to impart the required beneficial effect on the subject.
  • Preparations of postbiotics typically contain the inanimate probiotic bacteria and can also retain microbe-produced substances, such as metabolites, proteins, or peptides, which may contribute to the overall health effect conferred by a postbiotic, but such microbe-produced substances are not essential to a postbiotic.
  • the amount of inanimate probiotic bacteria (and/or their component parts (e.g., cellular debris) and/or their metabolites) in the postbiotic composition may be referred to as a therapeutically effective amount. Appropriate amounts can readily be identified by a person skilled in the art. Further details and examples are provided elsewhere herein.
  • inanimate refers to a bacterium that is no longer alive, or, in other words, dead or inactivated, and may comprise non-viable whole cells, cellular fragments, proteins, or peptides.
  • Components derived from inanimate microorganisms may comprise byproducts such as metabolites.
  • Appropriate metabolites are well known in the art and include SCFAs (such as butyrate, acetate, and/or propionate), secondary bile acid, and tryptophan metabolites (such as ILA).
  • Postbiotic compositions comprise at least one inanimate Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and/or Clostridium paraputrificum or at least one Clostridium perfringens metabolite, Clostridium baratii metabolite, Clostridium tertium metabolite and/or Clostridium paraputrificum metabolite.
  • Clostridium perfringens selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and/or Clostridium paraputrificum or at least one Clostridium perfringens metabolite, Clostridium baratii metabolite, Clostridium tertium metabolite and/or Clostridium paraputrificum metabolite.
  • the postbiotic composition comprises at least one inanimate Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and/or Clostridium paraputrificum.
  • the composition is beneficial to the overall health of an individual (referred to as a subject herein) that consumes it.
  • the postbiotic composition comprising at least one inanimate Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and/or Clostridium paraputrificum imparts its beneficial effects in the gut of the subject, and therefore improves the gut health of the subject.
  • the postbiotic composition may comprise at least two inanimate Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and/or Clostridium paraputrificum.
  • the postbiotic composition may comprise inanimate Clostridium perfringens and inanimate Clostridium baratii.
  • the postbiotic composition may comprise inanimate Clostridium perfringens and inanimate Clostridium tertium.
  • the postbiotic composition may comprise inanimate Clostridium perfringens and inanimate Clostridium paraputrificum.
  • the postbiotic composition may comprise inanimate Clostridium paraputrificum and inanimate Clostridium tertium.
  • the postbiotic composition may comprise inanimate Clostridium paraputrificum and inanimate Clostridium baratii.
  • the postbiotic composition may comprise inanimate Clostridium baratii and inanimate Clostridium tertium.
  • the postbiotic composition may comprise at least three inanimate Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and/or Clostridium paraputrificum.
  • the postbiotic composition may comprise inanimate Clostridium perfringens, inanimate Clostridium baratii, inanimate Clostridium tertium and inanimate Clostridium paraputrificum.
  • Clostridium can for example be made inanimate by killing at high temperature and pressure. It can for example also be removed by sterile filtration. Such methods are well known in the art.
  • the postbiotic composition comprises metabolites from at least one Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum.
  • the composition is beneficial to the overall health of an individual (referred to as a subject herein) that consumes it.
  • the postbiotic composition comprising metabolites from at least one Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum imparts its beneficial effects in the gut of the subject, and therefore improves the gut health of the subject.
  • the postbiotic composition may comprise metabolites from at least two Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and/or Clostridium paraputrificum.
  • the postbiotic composition may comprise metabolites from Clostridium perfringens and Clostridium baratii.
  • the postbiotic composition may comprise metabolites from Clostridium perfringens and Clostridium tertium.
  • the postbiotic composition may comprise metabolites from Clostridium perfringens and Clostridium paraputrificum.
  • the postbiotic composition may comprise metabolites from Clostridium paraputrificum and Clostridium tertium. In another example, the postbiotic composition may comprise metabolites from Clostridium paraputrificum and Clostridium baratii. In another example, the postbiotic composition may comprise metabolites from Clostridium baratii and Clostridium tertium. In another example, the postbiotic composition may comprise metabolites from at least three Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and/or Clostridium paraputrificum. In another example, the postbiotic composition may comprise metabolites from Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum.
  • Clostridium perfringens metabolite refers to metabolites originating from the metabolic activity of these Clostridium species, respectively, in particular when grown on one or more HMOs as a carbon source.
  • a Clostridium perfringens metabolite, Clostridium baratii metabolite, Clostridium tertium metabolite and/or Clostridium paraputrificum metabolite can for example be a short chain fatty acid (such as butyrate, acetate, and/or propionate), secondary bile acid, and/or tryptophan metabolites (such as ILA).
  • a short chain fatty acid such as butyrate, acetate, and/or propionate
  • secondary bile acid such as ILA
  • a postbiotic composition may comprise metabolites from at least one Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium, and/or Clostridium paraputrificum due to the postbiotic composition being an in vitro cell culture product.
  • the postbiotic composition may be generated by in vitro cell culture of the at least one Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and/or Clostridium paraputrificum.
  • In vitro cell culture of the at least one Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and/or Clostridium paraputrificum may be for a sufficient time period (and under appropriate conditions) to generate metabolites from the one or more Clostridium species.
  • the in vitro cell culture of the at least one Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and/or Clostridium paraputrificum may be performed by culturing the at least one Clostridium species with a prebiotic for a sufficient time period (and under appropriate conditions) to generate the metabolites.
  • the in vitro cell culture of the at least one Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and/or Clostridium paraputrificum may be performed by culturing the at least one Clostridium species with a MMO for a sufficient time period (and under appropriate conditions) to generate the metabolites.
  • the in vitro cell culture of the at least one Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and/or Clostridium paraputrificum may be performed by culturing the at least one Clostridium species with a HMO for a sufficient time period (and under appropriate conditions) to generate the metabolites.
  • the postbiotic composition may then be generated by removing the Clostridium species from the in vitro cell culture after the metabolites have been generated. Any appropriate method may be used to remove the Clostridium species, for example filtration, centrifugation etc.
  • a postbiotic composition may therefore be generated by culturing the appropriate Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum anaerobically in the presence of a suitable MMO under appropriate culture conditions.
  • Clostridium perfringens may be cultured in the presence of a HMO selected from: LNnT, 6SL, 2FL, DSLNT, LNFP-I and/or LNT under appropriate culture conditions.
  • a HMO selected from: LNnT, 6SL, 2FL, DSLNT, and/or LNT under appropriate culture conditions.
  • Clostridium perfringens may be cultured in the presence of a HMO selected from: LNnT, 6SL, 2FL, and/or DSLNT under appropriate culture conditions.
  • Clostridium perfringens may be cultured in the presence of a HMO selected from: LNnT, 6SL and/or DSLNT under appropriate culture conditions.
  • Clostridium perfringens may be cultured in the presence of a HMO selected from: LNnT and/or 6SL under appropriate culture conditions.
  • Clostridium perfringens may be cultured in the presence of LNnT under appropriate culture conditions.
  • Clostridium perfringens may be cultured in the presence of 6SL under appropriate culture conditions.
  • Clostridium baratii may be cultured in the presence of a HMO selected from: LNnT, and/or LNT under appropriate culture conditions.
  • a HMO selected from: LNnT, and/or LNT under appropriate culture conditions.
  • Clostridium baratii may be cultured in the presence of LNnT.
  • Clostridium baratii may be cultured in the presence of LNT under appropriate culture conditions.
  • Clostridium tertium may be cultured in the presence of a HMO selected from: LNnT, and/or LNT under appropriate culture conditions.
  • a HMO selected from: LNnT, and/or LNT under appropriate culture conditions.
  • Clostridium tertium may be cultured in the presence of LNnT.
  • Clostridium tertium may be cultured in the presence of LNT under appropriate culture conditions.
  • Clostridium paraputrificum may be cultured in the presence of a HMO selected from: LNnT, and/or LNT under appropriate culture conditions.
  • a HMO selected from: LNnT, and/or LNT under appropriate culture conditions.
  • Clostridium paraputrificum may be cultured in the presence of LNnT.
  • Clostridium paraputrificum may be cultured in the presence of LNT under appropriate culture conditions.
  • Clostridium perfringens and Clostridium baratii may be cultured in the presence of a HMO selected from: LNnT, 6SL, 2FL, DSLNT, LNFP-I and/or LNT under appropriate culture conditions.
  • a HMO selected from: LNnT, and/or LNT under appropriate culture conditions.
  • Clostridium perfringens and Clostridium tertium may be cultured in the presence of a HMO selected from: LNnT, 6SL, 2FL, DSLNT, LNFP-I and/or LNT under appropriate culture conditions.
  • a HMO selected from: LNnT, and/or LNT under appropriate culture conditions.
  • Clostridium perfringens and Clostridium paraputrificum may be cultured in the presence of a HMO selected from: LNnT, 6SL, 2FL, DSLNT, LNFP-I and/or LNT under appropriate culture conditions.
  • a HMO selected from: LNnT, and/or LNT under appropriate culture conditions.
  • Clostridium perfringens, Clostridium tertium, Clostridium baratii and Clostridium paraputrificum may be cultured in the presence of a HMO selected from: LNnT, 6SL, 2FL, DSLNT, LNFP-I and/or LNT under appropriate culture conditions.
  • a HMO selected from: LNnT, 6SL, 2FL, DSLNT, LNFP-I and/or LNT under appropriate culture conditions.
  • Clostridium perfringens, Clostridium tertium, Clostridium baratii and Clostridium paraputrificum may be cultured in the presence of a HMO selected from: LNnT, and/or LNT under appropriate culture conditions.
  • Appropriate culture conditions include anaerobic culture at around 37°C, for a period of at least 2 days, typically at least 5 or 6 days), optionally whilst shaking (e.g. at 130 rpm).
  • the postbiotic composition may then be generated by removing the Clostridium species from the cell culture. Any appropriate method may be used to remove the Clostridium species, for example filtration, centrifugation etc. Centrifugation may be for at least 5000g for at least 5 minutes at about 4°C. Fitration may be using a 0.22 pm filter. Centrifugation for at least 5000g for at least 5 minutes at about 4°C may be combined with fitration using a 0.22 pm filter.
  • the postbiotic composition may alternatively be generated by heat treating the Clostridium species in the cell culture to ensure that they are inanimate.
  • the postbiotic composition may include the entire cell culture, with the exception of live Clostridium species.
  • compositions provided herein may be administered to the subject in any suitable format and by any appropriate means.
  • the compositions described herein are for oral use.
  • the compositions described herein are typically comestible (also referred to as edible herein).
  • the composition may be in the form of a liquid medium, gel medium, powder, dissolvable medium, chewable medium, or any other ingestible medium. This includes, without limitation, tablets, capsules (including a gelatin capsules), pills, caplets, yogurts, freeze dried products, granules, syrups, drinks, food and the like. Suitable ways of preparing such compositions are well known in the art.
  • composition in a powder, liquid or solid form.
  • compositions described herein may also contain conventional food supplement fillers and extenders such as, for example, a flour, a binder, a neutraceutical compound or formulation, an amino acid, a vitamin, or a mineral.
  • conventional food supplement fillers and extenders such as, for example, a flour, a binder, a neutraceutical compound or formulation, an amino acid, a vitamin, or a mineral.
  • the bacteria described herein may be dried with a food product as described in WO98/10666, which is incorporated herein by reference in its entirety. Accordingly, the Clostridium species may be dried at the same time with juices, milk-based products or vegetable milks, for example, yielding a dried product already comprising the Clostridium species. This product may later be reconstituted with an aqueous liquid such as milk or water.
  • the composition may be a milk product.
  • a milk product is any comestible composition that comprises animal milk (obtained from a mammal) or a milk substitute (such as plant-based milk products).
  • the milk product may be in liquid, solid or powder form.
  • a milk product may comprise animal milk or a milk substitute.
  • animal milk include, but are not limited to, bovine, goat, sheep, camel, donkey, and reindeer milk. Human milk is also encompassed by this term.
  • a non-human or non-animal milk product may also be referred to as a “milk substitute” herein.
  • Milk substitutes therefore include plant milk, such as almond, soy, oat, coconut, pea, hemp, spelt, rice, pistachio, walnut, macadamia, flax, banana, cashew, hazelnut, quinoa, and sesame milk.
  • Milk substitutes also include modified milk, such as infant formula.
  • a milk product includes, but is not limited to, cheese, butter, cream, yoghurt, ghee, condensed milk, ice cream, buttermilk, milkshake, and whey etc.
  • a milk product also includes milk-based drinks or powders; and drinks or powders based on milk substitutes.
  • the milk product may comprise human donor breast milk.
  • the milk product may also be a milk product that has been generated in vitro.
  • it may be milk that has been produced by mammary organoids.
  • the milk product may be a modified milk product.
  • it may comprise modified milk that has been adapted for the subject of interest.
  • modified milk product is infant formula, which comprises cow’s milk that has been treated to make it more suitable for the subject of interest (e.g. human infants).
  • the composition is an infant milk product that is selected from the group consisting of: infant formula, a starter infant formula, a follow-on or follow-up infant formula, a baby food, or an infant cereal composition.
  • infant formula As used herein, the terms “formula milk”, “formula”, “baby formula”, “growing-up milk”, or “infant formula” are interchangeable and are intended to represent the substitute for human or animal breast milk which is given to infant humans or animals (0-36 months of age).
  • the infant formula may be powdered, concentrated liquid formula, or ready-to-use formula.
  • a milk product is therefore provided herein that comprises a probiotic composition for improving the gut microbiome and/or gut health of a subject, the composition comprising at least one Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum.
  • a milk product is also provided herein that comprises a postbiotic composition for improving the gut microbiome and/or gut health of a subject, the composition comprising at least one inanimate Clostridium species selected from the group consisting of: Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum.
  • a milk product is also provided herein that comprises a postbiotic composition for improving the gut microbiome and/or gut health of a subject, the composition comprising metabolites from at least one Clostridium species selected from the group consisting of: a Clostridium perfringens, Clostridium baratii, Clostridium tertium and Clostridium paraputrificum.
  • a milk product may also be a prebiotic composition as described herein.
  • the probiotic and/or postbiotic compositions provided herein reduce pathogen overgrowth in the gut, promote gut development, promote gut maturation, promote immunity, decrease gut inflammation, and/or promote enteral feeding tolerance in the subject.
  • compositions provided herein are for improving the gut microbiome and/or gut health of a subject.
  • the terms “improving” or “improve” refer to altering the bacterial composition of the gut microbiome in a beneficial way or altering the gut health of the subject in a beneficial way.
  • it refers to altering the relative abundance of a variety of bacterial species in the gut microbiome of the subject in a beneficial manner (e.g. to move from a state of dysbiosis of the gut microbiome towards a state of eubiosis).
  • Eubiosis of the gut microbiome refers to the healthy and balanced state of bacterial populations within the gut.
  • Dysbiosis of the gut microbiome is a negative alteration in the relative abundance of bacterial species in the gut and is associated with disease.
  • Dysbiosis may also be referred to as a disturbance of eubiosis.
  • Dysbiosis of the gut microbiome can be caused by infections, inflammation, diet, xenobiotics (including antibiotics, drugs, food additives), and birth route.
  • Methods of determining whether the gut microbiome has been improved, and identifying eubiosis and dysbiosis of the gut microbiome are well known. For example, see US2022/0313759, which provides several assays for determining an improvement in the gut microbiome, which are incorporated herein in their entirety.
  • Methods for improving the gut microbiome and/or gut health of a subject are also well known and include consumption of exogeneous prebiotics, probiotics and/or postbiotics.
  • Improvement of the gut microbiome and/or improving gut health can provide one or more beneficial effects. For example, it may reduce pathogen overgrowth in the gut, promote gut development, promote gut maturation, promote immunity, decrease gut inflammation, and/or the promote enteral feeding tolerance in the subject.
  • beneficial effects can readily be identified by a person of skill in the art, for example by comparing one or more of pathogen overgrowth, gut development, gut maturation, gut inflammation, enteral feeding tolerance etc in the subject before and after compositions of the invention have been consumed by the subject for an appropriate length of time. Appropriate consumption regimens for probiotics to have a beneficial effect are known in the art.
  • Improvement of the gut microbiome can in turn lead to subsequent improvements for the subject such as an improved eye sight (e.g., an improvement in retinopathy of prematurity (ROP)) or improved respiratory tract function (e.g. improved respiratory tract function in subjects with Bronchopulmonary dysplasia (BPD)).
  • ROP retinopathy of prematurity
  • BPD Bronchopulmonary dysplasia
  • Enrichment of Enterobacteriaceae in the gut microbiome of preterm infants has been associated with ROP (Skondra et al., J AAPOS.
  • compositions provided herein may be of benefit to subjects with retinopathy of prematurity (ROP) and Bronchopulmonary dysplasia (BPD)).
  • ROP retinopathy of prematurity
  • BPD Bronchopulmonary dysplasia
  • the composition may be used as a supplement by these subjects, to improve the symptoms and signs or disease.
  • compositions described herein may also be used to reduce the relative abundance of one or more pathobionts in the gut of a subject.
  • the compositions may be used to inhibit the growth of one or more pathobionts in the gut of a subject.
  • the compositions may be used to inhibit the growth of e.g. one or more of E. coli, E. faecalis, K. oxytoca and/or K. pneumoniae. This is particularly applicable to the postbiotic compositions of the invention, as shown in the examples section below.
  • compositions described herein may also be used to reduce Enterobacteriaceae relative abundance.
  • compositions described herein may also be used in the treatment or prevention of a gastrointestinal disorder, allergy, nappy rash, colic, or a symptom thereof in a subject.
  • gastrointestinal disorder refers to disorders and diseases of the digestive system (namely the oesophagus, stomach, small intestine, large intestine, and/or rectum) or accessory organs (such as the liver, pancreas, and gallbladder). It also refers to disorders that originate from problems with the digestive system.
  • a subject with a gastrointestinal disorder will commonly experience symptoms including, but not limited to, diarrhoea, abdominal pain, gastrointestinal bleeding, and/or intestinal obstruction.
  • a gastrointestinal disorder can be either a functional gastrointestinal disorder or an organic gastrointestinal disorder.
  • a functional gastrointestinal disorder is not associated with any physiological changes.
  • Non-limiting examples of functional gastrointestinal disorders include irritable bowel syndrome (IBS), gastroesophageal reflux disease, functional dyspepsia, functional nausea and vomiting, functional abdominal pain, functional constipation, and faecal incontinence.
  • An organic gastrointestinal disorder has measurable physiological changes and often results from intestinal inflammation.
  • Non-limiting examples of organic gastrointestinal disorders include Crohn’s disease, ulcerative colitis, coeliac disease, inflammatory bowel disease (IBD), chronic gastrointestinal infections, microscopic colitis, intestinal inflammation, colitis, necrotising enterocolitis (NEC), late-onset sepsis, and focal intestinal perforation.
  • compositions described herein may also be used in the treatment or prevention of a gastrointestinal disorder, selected from the group consisting of: intestinal inflammation, irritable bowel syndrome, colitis, necrotising enterocolitis, focal intestinal perforation, late- onset sepsis, and inflammatory bowel disease.
  • a gastrointestinal disorder selected from the group consisting of: intestinal inflammation, irritable bowel syndrome, colitis, necrotising enterocolitis, focal intestinal perforation, late- onset sepsis, and inflammatory bowel disease.
  • intestinal inflammation covers both acute and chronic inflammation of the tissues in a subject’s digestive tract, and is classified by redness (rubor), swelling (tumour), pain (dolor), and/or loss of function (functio laesa) as a result of the subject’s body’s reaction against injury and infection orchestrated by the immune system.
  • irritable bowel syndrome refers to a group of symptoms that occur together, including, but not limited to, recurrent stomach cramps, bloating, distension, diarrhoea, and/or constipation.
  • colitis refers to inflammation of the lining of the large intestine (colon). Any disease or disorder which results in acute or chronic inflammation of the large intestine falls under this term. Non-limiting causes of colitis include infections caused by viruses, parasites or bacteria, Crohn’s disease, ulcerative colitis, necrotising enterocolitis. Colitis commonly manifests as abdominal pain and bloating, bloody stools, tenesmus, dehydration, diarrhoea, and/or fever.
  • NEC enterocolitis
  • intestinal perforation refers to the loss of continuity of the gastrointestinal or bowel wall and is a common complication of a number of diseases or disorders.
  • Non-limiting examples resulting in intestinal perforation comprise appendicitis, cancers affecting the digesting system, cancers of the digestive system, diverticulitis, hernias, bowel obstruction, gall stones, colitis, trauma, ischaemia, inflammation, and necrotising enterocolitis.
  • FIP focal intestinal perforation
  • the term “sepsis” is defined as the dysregulated host response to infection encompassing a spectrum of disease/disorder, ranging from minor signs and symptoms to life-threatening organ dysfunction and death. Infections that lead to sepsis most often start in the lung, urinary tract, skin, or gastrointestinal tract. Sepsis may progress to septic shock, which comprises a dramatic drop in blood pressure which can damage vital organs and can be fatal.
  • the term “early-onset sepsis” as used herein refers to sepsis onset most often appearing within 24 to 48 hours of birth, and has commonly contracted the infection from the mother before or during delivery.
  • late-onset sepsis refers to sepsis onset after 72 hours and up to 90 days of life and is the pathogens responsible are usually acquired from the environment during or after delivery. It is more common in preterm infants.
  • IBD inflammatory bowel disease
  • Ulcerative colitis and Crohn's disease are long-term conditions that involve inflammation of the gut. Ulcerative colitis only affects the colon (large intestine). Crohn's disease can affect any part of the digestive system, from the mouth to the anus. Symptoms of IBD include pain, cramps or swelling in the tummy; recurring or bloody diarrhoea; weight loss and extreme tiredness.
  • compositions provided herein result in an improvement of the gut microbiome and/or gut health of a subject, which can provide one or more beneficial effects. For example, it may reduce pathogen overgrowth in the gut, promote gut development, promote gut maturation, promote immunity, decrease gut inflammation, and/or the promote enteral feeding tolerance in the subject.
  • SI BO small intestinal bacterial overgrowth
  • pathogen overgrowth refers to the presence of excess colonic bacteria in the small intestine resulting in an unbalanced microbiota.
  • SI BO Commonly present in SI BO are Escherichia coli, Aeromonas species, and Klebsiella species, but Bacteroides, Clostridium, Peptostreptococcus, and Micrococcus species are also responsible.
  • gut development refers to the process of establishing the microbiota from birth.
  • gut maturation refers to the process of the maturing of the microbiota composition to an adult-like composition and function between three and five years of age.
  • Immunity as used herein broadly refers to the subject’s state of being insusceptible or resistant to a pathogen or infectious disease. Immunity is governed by the immune system, a system of defence comprising a complex network of organs, cells, tissues, and other components, such as proteins, which act together to help protect the subject.
  • the three types of immunity are innate, adaptive, and passive. Innate immunity is the system with which you were born with and is characterised by being non-specific. Non-limiting examples of innate immunity comprise stomach acid, the skin barrier, mucus, and enzymes in saliva and skin oils.
  • Adaptive immunity is the system conferring acquired immune responses or ‘active’ immunity, resulting in immunological memory after an initial response to, usually, a pathogen.
  • Nonlimiting examples of adaptive immunity comprise an immature B cell becoming a plasma cell and producing specific antibodies to an epitope on an antigen.
  • Passive immunity is immunity provided by the administering of exogenous immune components (either naturally or artificially) which provide short-term protection to the subject.
  • passive immunity comprise a baby receiving its mother’s antibodies through the placenta or breast milk (natural passive immunity) or the administering of antibodies to neutralise a toxin (artificial passive immunity).
  • enteral feeding refers to nutrition taken through the mouth or through a tube that goes directly to the stomach or small intestine. The latter meaning is often used in a medical setting.
  • enterral feeding tolerance as used herein is intended to refer to the absence of an adverse reaction to the delivery of nutrition or food taken through the mouth or through a tube that goes directly to the stomach or small intestine.
  • compositions provided herein may also be used to treat or prevent an allergy in a subject.
  • allergy refers to a subject’s immune system’s hypersensitive response to a foreign, but inert, substance (i.e. , an allergen) in the environment. Allergies can occur on a range of severity, from a blocked nose to anaphylaxis. Allergic reactions can be mediated by IgE or be non-lgE in nature.
  • allergens can include food, insect stings, latex, and drugs.
  • Non-limiting examples of food allergens in allergenic food include celery, gluten containing cereal (such as barley, wheat, and oats), crustaceans (such as crabs, prawns, and lobsters), fish, milk, molluscs (such as mussels and oysters), eggs, mustard, peanuts, sesame, soybeans, sulphur dioxide and sulphites and tree nuts (such as hazelnuts, walnuts, almonds, cashews, pecans, macadamia nuts, pistachio, and brazil nuts).
  • celery such as barley, wheat, and oats
  • crustaceans such as crabs, prawns, and lobsters
  • fish milk
  • molluscs such as mussels and oysters
  • eggs mustard, peanuts, sesame, soybeans, sulphur dioxide and sulphites
  • tree nuts such as hazelnuts, walnuts, almonds, cashews, pecans, macadamia nuts, p
  • CMA cows' milk allergy
  • cows' milk protein allergy is one of the most common childhood food allergies. CMA typically develops when cows' milk is first introduced into the baby's diet either in formula or when your baby starts eating solids. More rarely, it can affect babies who are exclusively breastfed because of cows' milk from the mother's diet passing to the baby through breast milk.
  • immediate CMA - where symptoms typically begin within minutes of having cows' milk delayed CMA - where symptoms typically begin several hours, or even days, after having cows' milk.
  • Cows' milk allergy can cause a wide range of symptoms, including: skin reactions - such as an itchy rash or swelling of the lips, face and around the eyes digestive problems - such as stomach ache, vomiting, colic, diarrhoea or constipation hay fever-like symptoms - such as a runny or blocked nose eczema that does not improve with treatment
  • CMA can cause severe allergic symptoms that come on suddenly, such as swelling in the mouth or throat, wheezing, cough, shortness of breath, and difficult, noisy breathing.
  • compositions provided herein may also be used to treat or prevent nappy rash in a subject.
  • nappy rash refers to the acute inflammatory reaction of the skin in contact with a nappy. It can be characterised by inflamed, irritated, red, and/or dry skin in contact with the nappy and is primarily characterised as an irritant contact dermatitis. It is commonly caused by the prolonged skin contact with the subject’s urine or faeces, skincare preparations, or detergents and fabric softeners.
  • compositions provided herein may also be used to treat or prevent an colic in a subject.
  • colic and infantile colic as used herein are interchangeable and refer to the paroxysms of crying of a healthy infant when there is no obvious cause for the infant to be crying. Colic is a pattern of crying, which occurs daily and often at the same time of day which occurs in up to a quarter of newborn babies. It is most common during the first six weeks of life and will usually resolve by four to six months independent of therapeutic intervention.
  • compositions provided herein may reduce the proportion of pathogenic bacteria in the microbiome of the subejct.
  • the pathogenic bacteria are Enterobacteriaceae (e.g., one or more of Salmonella, E. coli, or Klebsiella).
  • the pathogenic bacteria are reduced by greater than 10%, 15%, 25%, 50%, 75%, 80%, or 85% by the treatment.
  • compositions provided herein may reduce the antibiotic resistance gene load in the subject.
  • One or more genes of the antibiotic resistance gene load may be reduced by greater than 10%, 15%, 25%, 30%, 45%, 50%, 75% or 85%.
  • the compositions provided herein may reduce the levels of lipopolysaccharide (LPS) and/or pathogenic bacteria in the gut of the subject.
  • LPS lipopolysaccharide
  • compositions provided herein may reduce the frequency of bowel movements in the subject as compared to a dysbiotic subject.
  • the stool composition of an subject be altered as compared to a dysbiotic subject.
  • the firmness/consistency of the stool composition of the subject can be increased as compared to a dysbiotic subject.
  • the stool can be less watery.
  • compositions described herein may be of benefit to any appropriate subject.
  • subject as used herein is intended to include humans and animals.
  • subject include mammals, e.g., humans, dogs, cows, horses, pigs, sheep, goats, cats, mice, rabbits, rats, and transgenic non-human animals.
  • subjects include companion animals, e.g. dogs, cats, rabbits, and rats.
  • subjects include livestock, e.g., cows, pigs, sheep, goats, and rabbits.
  • subjects include thoroughbred or show animals, e.g. horses, pigs, cows, and rabbits. The subject may be an infant.
  • the subject is a human.
  • the subject may be a human infant.
  • the term “human infant” as used herein is intended to refer to a child in the first year of life.
  • the subject may be less than four weeks old, which may be referred to herein as “neonate”.
  • the subject may be born at term or preterm.
  • the subject may be born alive before 37 weeks of pregnancy, which may be referred to herein as a “preterm infant”.
  • the subject may be an infant who is small for their gestational age, which comprises an infant born with a birth weight less than the 10 th centile (based on age).
  • the subject may be an infant born by Caesarean-section (C-section).
  • the subject may be an infant prior to the NEC risk period. In some examples, the subject may be a newborn during the NEC risk period. In some examples, a subject may be a newborn post-NEC risk period. In this context, the NEC risk period may be defined as the first 10 to 40 days of life.
  • the subject may be an infant that is in (staying in) an NICU (neonatal intensive care unit). In some examples, the subject may be an infant that has been discharged from NICU within the last month.
  • the subject may be 0-3 months old.
  • a subject may be 3-12 months old.
  • a subject may be from 1-5 years old.
  • the subject may be 5-13 years old.
  • the subject may be 13+ years old. In some examples the subject may be an adult (18+).
  • the subject may be elderly (65+).
  • the subject may be an infant that has been hospitalised and/or is undergoing antibiotic treatment. Infants, including preterm infants on NICU, spending prolonged time in hospital will get colonised by higher levels of hospital acquired pathobiont bacteria and therefore in particular require a stabilization and/or improvement of the gut microbiome.
  • the subject can be dysbiotic.
  • “Dysbiotic” refers to the condition of dysbiosis (also called dysbacteriosis) and is characterized by a disruption to the microbiome resulting in an imbalance in the microbiota, changes in their functional composition and metabolic activities, or a shift in their local distribution.
  • Dysbiosis can refer to any flora such as the skin flora, gut flora, or vaginal flora.
  • the subject can be dysbiotic with regard to their gut microbiome.
  • examples of such subjects may be those that are undergoing antibiotic treatment.
  • Dysbiosis in a subject can be observed by the physical symptoms of the subject (e.g., diarrhea, digestive discomfort, inflammation, etc.) and/or by observation of the presence of free sugar monomers in the feces of the subject, an absence or reduction in specific Bifidobacteria populations, and/or the overall reduction in measured SCFA; more specifically, acetate and lactate. Additionally, the infant may have an increased likelihood of becoming dysbiotic based on the circumstances in the environment surrounding them (e.g., an outbreak of disease in the surroundings of the subject, formula feeding, cesarean birth, etc.). Dysbiosis in an infant can further be revealed by a low level of SCFA in the feces of said infant.
  • a dysbiotic infant may have (a) a watery stool, (b) Clostridium difficile levels of greater than 10 6 cfu/g feces, greater than 10 7 cfu/g feces, or greater than 10 8 cfu/g feces, (c) Enterobacteriaceae at levels of greater than greater than 10 6 , greater than 10 7 , or greater than 10 8 cfu/g feces, and/or (d) a stool pH of 5.5 or above, 6.0 or above, or 6.5 or above.
  • gut microbiome As used herein, the terms “gut microbiome”, “gut flora”, “gastrointestinal flora”, “intestinal flora”, “intestinal microbiome”, “microbiota”, and “microbiome” are interchangeable and are intended to represent the bacterial community present in the digestive tract of the subject. It is meant to reflect the variety of commensal and mutualistic species, and relative abundance of said bacterial species found in a healthy subject. It is the gut microbiota which functions to ferment non-digestible substrates like dietary fibres and endogenous intestinal mucus (prebiotics), metabolise nutrients, xenobiotic and drugs, maintain structural integrity of the mucosal barrier, immunomodulation, and confer pathogenic resistance. Methods of administration
  • compositions provided herein are for oral administration.
  • suitable routes of administration of the composition described herein may be via suppositories or feeding tubes directly into the digestive tract, including but not limited to, a jejunostomy tube, gastrostomy tube, or a nasojejunal tube.
  • compositions provided herein are intended as a supplement and may be administered regularly for effects to be maintained or persist.
  • probiotics typically adhere to a tissue of the host, such as the digestive tract. Once attached, the desirable bacteria are capable of multiplying and colonising, thereby altering the microbiota of a subject.
  • Probiotics can be mixed with various ingredients to create a product for consumption.
  • compositions provided herein are for administration to the subject at an appropriate (e.g. therapeutically effective) dose.
  • Appropriate doses are readily identifiable by a person of skill in the art.
  • the probiotic composition provided herein comprises at least 0.5 x 10 9 CFU of the Clostridium species per dose.
  • the probiotic composition provided herein may comprise at least 0.5 x 10 9 CFU of each Clostridium species per dose.
  • dose refers to the quantity of the Clostridium species administered or taken with one total serving, i.e. it resembles the total intake independent of the volume administered or taken, with one portion.
  • one portion refers to the recommended amount of the composition independent of the form. It may be a certain amount of tablets, pills, capsules or a certain amount of a (pre-packed) syrup, (pre-packed) powder, (pre-packed) solid beverage, (pre-packed) soup, or (pre-packed) liquid suspension.
  • CFU colony forming unit
  • the composition comprises at least 0.6 x 10 9 CFU per dose per strain, at least 0.6 x 10 9 CFU per dose per strain, at least 1 x 10 9 CFU per dose per strain, at least 2 x 10 9 CFU per dose per strain, at least 3 x 10 9 CFU per dose per strain, at least 4 x 10 9 CFU per dose per strain, at least 5 x 10 9 CFU per dose per strain, at least 6 x 10 9 CFU per dose per strain, at least 7 x 10 9 CFU per dose per strain, or at least 8 x 10 9 CFU per dose per strain.
  • the CFU per dose can vary between the two or three species or can be the same.
  • the composition is provided to the subject on a daily basis comprising from 0.1 billion to 500 billion cfu of bacteria/day.
  • the composition that is provided on a daily basis can include from 1 billion to 100 billion cfu/day or from 5 billion to 20 billion cfu/day.
  • the composition may be provided on a daily basis for at least 2, at least 5, at least 10, at least 20, or at least 30 days.
  • the recipient of the treatment can be a human infant.
  • the composition can be administrated orally or by other suitable routes.
  • the composition may be in the form of capsules, tablets, powders, granules, solutions, or suspensions etc.
  • the Clostridium species can be mixed with conventional excipients, such as gelatin, starch, lactose, magnesium stearate, talc, gum arabic and the like. It may also be advantageous to use less conventional excipients that, for example, make it possible to increase the ability of Clostridium species to be active in the gut. For example, cellobiose, maltose, mannose, salicine, trehalose, amygdalin, arabinose, melobiose, rhamnose and/or xylose may be added.
  • a capsule, pill, tablet, or syrup for oral administration should be stored in a manner so as to preserve its efficacy.
  • Methods of storage for probiotic compositions include but are not limited to refrigeration, freezing, and storing at room temperature. If stored at room temperature, the Clostridium species or compositions thereof should be stored in an air tight container.
  • the probiotic Clostridium species should arrive intactly in the small and large intestine the latter of which may be colonized.
  • the Clostridium species may be microencapsulated or enterically coated to provide a release profile that targets replacement or alteration of live Clostridium species at a pre-determined location within the gastrointestinal tract of a subject.
  • Such microencapsulation formulations and techniques may protect the live Clostridium species from the digestive actions of the stomach, duodenum, and jejunum of the intestine and allow administration, delivery or release to the gut or ileum of a subject.
  • Microencapsulated live Clostridium species and compositions thereof may be in various dosage forms, and they can be co-administered with drugs, foods, nutrients, vitamins, other beneficial substances, prebiotics, and other therapeutic agents such as pH encapsulated glucose, lipids or proteins that release in the distal small intestine at pH values between 7.0 and 8.0 in an amount sufficient to achieve the desired effect in a subject.
  • at least two coatings may be used to cover a tablet or capsule like form comprising the Clostridium species, wherein the outside coating is degraded in a pH environment of 5 to 6 and the inside coating is degraded in a pH environment of about 7 thereby releasing the Clostridium species in the ileum area.
  • An exemplary coating may include one or more of poly(dl-lactide-co- glycolide) chitosan, casein, chitosan (Chi) stabilized with PVA (poly-vinylic alcohol), a lipid, an alginate, carboxymethylethylcellulose (CMEC), cellulose acetate trimellitiate (CAT), hydroxypropylmethyl cellulose phthalate (HPMCP), hydroxypropylmethyl cellulose, ethyl cellulose, color con, food glaze and mixtures of hydroxypropylmethyl cellulose and ethyl cellulose, polyvinyl acetate phthalate (PVAP), cellulose acetate phthalate (CAP), shellac, copolymers of methacrylic acid and ethyl acrylate, and copolymers of methacrylic acid and ethyl acrylate to which a monomer of methylacrylate has been added during polymerization, and other methacrylic resins that are commercially available under
  • Multi-layer coatings using different polymers may also be applied.
  • the preferred coating weights for particular coating materials may be readily determined by those skilled in the art by evaluating individual release profiles for tablets, beads and granules prepared with different quantities of various coating materials. It is the combination of materials, method and form of application that produce the desired release.
  • compositions described herein may be administered once or more per day to a subject.
  • the administration amount can vary depending on the body weight of the subject, the severity of a subject’s condition, the subject’s desired outcomes, supplemental active ingredients included and microorganisms used therein.
  • Suitable dosages of Clostridium species or compositions thereof may be provided orally at a dosage rate of at least 10 milligrams to at least 1000 milligrams per day.
  • the dosage rate, effective as a food supplement and for establishing or increasing Clostridium species in the intestinal tract of a subject may be determined by known methods in the art.
  • Clostridium species or compositions thereof may be administered 1 , 2 3, 4, 5 or more times per week for a specified time period.
  • the specified time period may be at least one week.
  • the specified time period may be at least 1 , at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8 weeks or more.
  • administration may be continuous, for example a subject may continually take doses of Clostridium species or compositions thereof even after effects the beneficial effects have been achieved. In the context of medical conditions and diseases that may reduce muscle mass and/or strength, continuous administration may help prevent or reduce the muscle wasting effects of the condition or disease.
  • an “effective amount” refers to an amount of a Clostridium species sufficient to achieve the desired function or activity in the subject and is acceptable to the subject (i.e. does not cause adverse effects in the subject).
  • an effective amount may be an amount of Clostridium species that provides some improvement or benefit to a subject having a disease, condition, or disorder in which a loss of muscle mass and/or muscle strength occurs.
  • an “effective amount” or “therapeutically effective amount” with reference to therapeutic uses and methods is an amount that provides some alleviation, mitigation, and/or decrease in at least one clinical symptom of the disease, condition, or disorder in which a loss of muscle mass and/or muscle strength occurs.
  • Clostridium species and/or the metabolite thereof in the preparation of the compositions described herein can vary depending on the mode of administration and the requirements of the subject. For example, the severity of a subject’s condition or the subject’s desired result.
  • stool samples were collected from preterm infants in the neonatal intensive care unit at Newcastle, UK. Preterm infant stool samples underwent microbiological culture to isolate a range of novel bacterial isolates. Growth curves were then performed to determine which isolates were capable of growing on specific individual HMOs as the sole carbon source.
  • agar media including brain heart infusion (BHI), Transoligosaccharide propionate (TOS), Bifidus Selective Medium (BSM), De Man, Rogosa and Sharpe (MRS), fastidious anaerobe agar (FAA), and yeast extract-peptone-dextrose (YPD).
  • BHI brain heart infusion
  • TOS Transoligosaccharide propionate
  • BSM Bifidus Selective Medium
  • MMS De Man
  • FAA fastidious anaerobe agar
  • YPD yeast extract-peptone-dextrose
  • Glycerol stocks were part-thawed and transferred to 5ml broth based on the isolate’s preferred medium.
  • Zhang Mills Block 1 (ZMB1) without glucose was prepared, and various carbon sources were tested in 1% concentration. Controls consisted of no carbon source, glucose, and lactose. Tested HMOs were 2’FL, DSLNT, LNT, LNnT, LNFP I, 6SL. The overnight growth for each isolate was centrifuged at 5000g for 5 mins at 4°C, and the pellet was resuspended in the same amount of anaerobic PBS. 20pl of the bacteria in PBS was aliquoted into 180p I of media, and the growth was measured in a Cerillo Stratus plate reader for 150 hours. All isolates were tested in triplicate, and wells with media only were included in each plate to check for contamination.
  • Clostridium species and Bifidobacterium species were able to grow on HMOs.
  • Clostridium the following species were found to use at least one HMO, which has not previously been reported: C. perfringens, C. baratii, C. tertium and C. paraputrificum (Fig. 1).
  • Bifidobacterium the following species were found to use at least one HMO, which have all been reported previously: B. infantis, B. bifidum, B. breve, and B. longum (Fig. 1).
  • the dendrogram shows that 4 strains of C. perfringens cluster closely with a B. infantis strain. A further 3 strains of C. perfringens and a strain of C.
  • tertium also form a larger cluster with B. infantis from the next branch up.
  • Another cluster is comprised of a C. tertium, C. paraputrificum and C. baratii, which have grouped with 3 strains of B. breve and a B. longum.
  • the final HMO- utilising cluster formed is comprised of another C. paraputrificum alongside an additional B. breve.
  • DLSNT due to limited DLSNT, not all strains of Clostridium could be tested for growth on this HMO.
  • two C. perfringens were able to use this HMO.
  • Bifidobacterium strains tested on DLSNT B. bifidum and a single
  • B. breve showed growth. Growth of B. bifidum on DSLNT was higher than that seen for both
  • C. perfringens strains and the growth of B. breve was either lower or comparable to them. Of all Bifidobacterium strains, only B. animalis was not tested on DLSNT and it is unlikely this strain can use this HMO given it could not use any other HMO or lactose for growth. Aside from DLSNT, all C. perfringens, C. baratii, and C. tertium, and one C. paraputrificum strain were able to use LNnT. C. baratii, C. tertium, both C. paraputrificum and one other strain of C. perfringens could use LNT. Most C. perfringens strains could use 6SL (6/7) and 2FL (4/7).
  • HMO-utilising bacteria produce short chain fatty acids, convert aromatic amino acids into aromatic lactic acids (e.g., indolelactic acid; ILA), and potentially release other functionally important compounds that have important immunomodulatory roles in host health.
  • ILA indolelactic acid
  • ILA has been shown to limit T cell activation and reduce a pro-inflammatory response by inducing galectin-1 in TH2 and TH17 cells during helper T cell polarisation (Henrick et al. Cell. 2021 Jul 22;184(15)).
  • galectin-1 in TH2 and TH17 cells during helper T cell polarisation
  • Clostridium are able to produce butyrate when from dietary glycans and higher butyrate has previously been linked to reduced NEC risk.
  • HMO-utilising bacteria are widely considered probiotic bacteria and higher levels of HMO-utilising bacteria in the gut has been associated with reduced inflammation and improved health.
  • the disclosure provides a method for increasing Clostridium abundance in the gut, including strains that are able to use a range of HMOs including DSLNT.
  • preterm infants diagnosed with NEC provided longitudinal stool samples spanning the disease course.
  • preterm infants diagnosed with NEC provided longitudinal stool samples spanning the disease course.
  • healthy controls who did not develop NEC also provided longitudinal stool samples.
  • DNA was extracted from 100mg of stool sample using the DNeasy PowerSoil Kit (QIAGEN). Library prep was performed using the Nextera DNA Flex Kit. Sequencing was performed on the HiSeq X Ten (Illumina) with a target read depth of 10M reads per sample with a read length of 150bp paired end reads. Taxonomic profiling of metagenomic samples was performed using MetaPhlAn v.2.0. All samples containing ⁇ 100,000 were removed from the analysis.
  • Clostridium perfringens was elevated early in life in healthy (no-NEC) preterm infants in comparison to preterm infants diagnosed with NEC (Fig. 2). This was especially apparent over the critical period of NEC risk between days 10 and 40 when most NEC is diagnosed (Fig. 2). In contrast, the six most abundant Bifidobacterium species showed relatively similar trajectories between healthy and NEC diagnosed preterm infants (Fig. 3).
  • GLMMs of Clostridium perfringens before (preNEC) and after (postNEC) NEC diagnosis compared to healthy preterm infants as the reference group show a significant increase in C. perfringens in healthy preterm infants prior to disease (Fig. 4). No difference was shown in C.
  • This disclosure provides a method of increasing Clostridium abundance, including but not limited to Clostridium perfringens, in the (preterm) gut to reduce the risk of NEC and other diseases.
  • a loopful of a glycerol stock was streaked out across an agar plate of the isolate’s preferred medium and incubated anaerobically at 37°C overnight.
  • a single colony was transferred to 5ml broth based on the isolate’s preferred medium and incubated anaerobically at 37°C overnight.
  • Two 5 mL aliquots of ZMB1 were prepared. Glucose (5 mg/ml) was added one aliquot, while the HMOs (5 mg/ml of each) known to sustain growth of the isolate were added to the second aliquot. The OD600 of the overnight growth of the isolate was measured and the culture diluted to OD 1.
  • Glycerol stocks of either pathobionts or Bifidobacterium were streaked out on agar plates of each isolate’s preferred medium and incubated anaerobically at 37°C overnight. Single colonies were then picked from these plates, transferred to 5ml broth based on each isolate’s preferred medium and incubated anaerobically at 37°C overnight.
  • a fresh batch of ZMB1 medium was prepared and split into 4. One of the ZMB1 aliquots was supplemented with glucose to concentration of 10 mg/mL, the second with glucose to a concentration of 20 mg/mL, and the third with the same HMOs used in the postbiotic to a total concentration of 10 mg/mL. The fourth aliquot was left without a carbon source.
  • the cultures were then incubated anaerobically at 37°C, with shaking at 110 rpm, until they each reach mid exponential growth phase. At this point, the OD600 of each was measured and volumes required to dilute them to an OD600 of 0.1 in 1.5 mL ZMB1 were calculated. The required volumes of the cultures were then centrifuged at 5000 G for 5 mins at 4°C and the supernatants removed.
  • the pellets were then resuspended in 1.5 mL ZMB1 + 20 mg/mL glucose.100 uL of each pathobiont was then added to either 1) 100 uL of ZMB1 with HMOs postbiotic, 2) 100 uL of ZMBI with glucose postbiotic, 3) 100 uL of sterile ZMB1 with HMOs medium, and 4) 100 uL of sterile ZMB1 medium (no carbon source). Following this set up, the minimum concentration of glucose in each well was 10 mg/mL. All experiments were performed in triplicate.
  • C. perfringens and C. tertium derived HMO postbiotics promoted the growth of three of the Bifidobacterium spp. tested (B. bifidum, B. breve and B. longum) during 72 hrs of incubation, compared to regular medium controls (Figs. 7 & 8).
  • the C. perfringens derived glucose postbiotic also produced similar growth promotion, demonstrating the effect was not solely dependent on HMO metabolism by the probiotic strain. The same was also true for the activity of the C. tertium glucose postbiotic on B. longum. However, for B. bifidum and B. breve, the C.
  • tertium HMO postbiotic had a stronger growth promoting effect, suggesting metabolism of HMOs by C. tertium may indeed result in the production of additional bifidogenic metabolites compared to metabolism on glucose.
  • C. perfringens and C. tertium derived HMO and glucose postbiotics all inhibited growth of B. infantis compared to regular medium controls (Figs. 7D & 8D).
  • this inhibition was weaker than the effect seen against the pathobionts above, as differences in growth between postbiotic and control conditions were not detectable at 10 hours of incubation, but instead only at 72 hours. This suggests the C. perfringens and C. tertium derived postbiotics would not interfere with initial B. infantis colonisation and establishment in the gut environment, as they likely would with the pathobionts tested above.
  • Bacteria were grown in their preferential media overnight before the co-cultures were set up in ZMB1 supplemented with 1% w/v of a mix of LNT, LNnT, 6SL, 2’FL and LNFP I (each HMO will have a final concentration of 0.2% w/v).
  • a starting total OD of 0.1 was used, and bacteria were cultured as a single culture, or as co-cultures in various proportions, 50%+50%, or 25%+75%.
  • a co-culture made by an equal amount of all bacteria was also tested. The growth was stopped at 24h, and 500ul of culture were harvested at the start and at the end of the experiment.
  • the cultures were centrifuged at 17000G for 5 mins, the supernatant was saved for further analysis, and the DNA was extracted from the pellet using the DNeasy Microbial Kit (Qiagen) following the manufacturer’s instructions.
  • the DNA was resuspended in 50ul of elution solution. Quantitative PCR was then used to determine the numbers of cells for each bacteria using species-specific primers. The specificity of each primer was tested against all the isolates included in the experiments.
  • Each reaction was composed of a total volume of 20pl of which 10pl of PowerllpTM SYBRTM Green Master Mix (Applied Biosystems), 1 l of template DNA, and forward and reverse primers to achieve the final concentration.
  • Caco-2 cells were cultured in Advanced DM EM, supplemented with FBS to 10% and GlutaMAX.
  • the cells were seeded at a density of 5000 cells per well, in a volume of 200 pL per well, across 96 well plates and incubated at 37°C and 5% CO2 for 24 hours.
  • the old medium was then removed, and the following conditions set up in 100 pL 1) DMEM only control, 2) ZMB1 medium, with no carbon source at 10%, 25%, 50% and 75% dilutions in DMEM, 3) 11x HMO postbiotics in separate wells at 10%, 25%, 50% and 75% dilutions in DMEM, 4) 12x glucose postbiotics in separate wells at 10%, 25%, 50% and 75% dilutions in DMEM. All conditions were set up in triplicate. The assays were then incubated at 37°C and 5% CO2 for 24 hours. Media was then removed from each well and replaced with 100 pL fresh DMEM.
  • MTS reagent is reduced by metabolically active cells into a formazan salt that is soluble in tissue culture medium, giving a detectable colour change which can be quantified by measuring absorbance at 490 nm using a plate reader.
  • the measured absorbance at 490 nm corresponds to the quantity of formazan produced, which in turn corresponds to the number of living cells in the culture.
  • the measured absorbance is directly proportional to the number of viable cells and allows the viability of a culture to be compared with others.
  • Fresh MTS reagent was prepared by adding phenazine methosulfate (PMS) to a concentration of 5% to MTS tetrazolium salt solution.
  • PMS phenazine methosulfate
  • C. perfringens derived HMO postbiotic can suppress inflammation and improve barrier function in a human intestinal epithelial organoid model. To identify how any observed effects in the organoid model compare to those induced by a B. infantis derived HMO postbiotic.
  • Intestinal epithelial organoid lines were established from intestinal crypts isolated from preterm neonate tissue, as described by Stewart et al. (Methods Mol Biol. 2020;2121:185- 198). Organoids were cultured and passaged as described in the same protocol.
  • Three dimensional organoids were processed into 15 two dimensional monolayers in 6.5 mm Transwells, following the protocol described by Fofanova et al. (bioRxiv 555755, 2019). Monolayers were then placed into the anaerobic co-culture system (Fofanova et al., bioRxiv 555755, 2019), which was in turn placed into an anaerobic chamber. Oxygen is flowed through the base of the co-culture unit, maintaining aerobic conditions on the basolateral sides of the monolayers, while the apical sides remain under the anaerobic conditions of the chamber. Thus, the physiological oxygen gradient of the gut epithelium is recreated in this model.
  • the trans-epithelial resistances (TEERs) of the monolayers were measured with an epithelial Ohm meter before the start and at the end of the experiment.
  • ANOVAs followed by Tukey’s Post Hoc tests were used to analyse pre-treatment and post-treatment TEERs as separate groups. Conditions within those groups with matching letters were not significantly different.
  • apical and basolateral supernatants were harvested for cytokine assays.
  • the first organoid co-culture experiment used C. perfringens derived HMO postbiotic (Fig. 11). No statistical difference was found between the ‘Control’, ‘Stimuli’ and ‘Postbiotic (10%) and Stimuli’ TEERs. There were statistical differences between the ‘Control’ and the ‘Postbiotic (25%)’ and ‘Postbiotic (25%) and Stimuli’ TEERs. These two 25% postbiotic conditions were also statistically different from the ‘Stimuli’ condition and induced the first and second highest average changes in TEER (Fig. 11 A). The larger increases in TEERs therefore appear to be a result of a biological activity of the postbiotic itself.
  • the postbiotic in the presence of microbially induced inflammatory insult, the postbiotic was able to increase barrier integrity of the preterm intestinal epithelium, which is a protective characteristic as described below.
  • the C. perfingens derived postbiotic was also found to inhibit the secretion of pro-inflammatory cytokines and chemokines from the organoid monolayers (Fig. 11B-I). Stimuli-induced apical and basolateral secretion of the pro-inflammatory neutrophil chemokine IL8 was reduced by the postbiotic, with no difference seen between 10% and 25% doses (Fig. 11B & C). Additionally, stimuli-induced apical and basolateral secretion of the chemokines CCL2 (Fig.
  • the ‘Postbiotic (25%)’ condition was also significantly different from ‘Control’. Taken together, these results suggest that the postbiotic did exert an effect upon monolayer as the C. perfringens postbiotic did. However, in contrast to the C. perfringens postbiotic, there was no significant difference between the postbiotic in isolation and ‘Stimuli’, meaning the activity of this postbiotic may be weaker than that of C. perfringens.
  • the B. infantis postbiotic also failed to inhibit stimuli-induced apical secretion of IL8, CCL7 and TNFa from the monolayers (Fig. 12B, F & H), as well as basolateral secretion of CXCL5 (Fig. 12J).
  • TEERs are widely accepted as reliable quantitative indicators of the integrity of cellular barriers and are regularly used to assess barrier function within in vitro gastrointestinal (Gl) tract models (Srinivasan et al., J Lab Autom. 2015 April ; 20(2): 107-126). Decreases in TEER have been directly associated with decreases in expression of tight junction proteins, increases in barrier permeability and increased secretion of inflammatory cytokines in gut models (Ghosh et al., Cell Mol Gastroenterol Hepatol 2021;11 :1463-1482). The inverse is also the case, that increased TEERs are associated with tightened cell junctions.
  • Intestinal epithelial integrity is particularly critical in preterm neonates, whose Gl tracts are physiologically immature and deficient in their barrier function and so are known to be “leaky” (Ma et al., mBio 2022, 13:e01299-22). Intestinal bacteria are therefore more freely able to translocate across the gut epithelium of these infants, causing infection and intestinal injury, which may in turn lead to NEC or sepsis. Promoting epithelial barrier integrity and maturation may therefore reduce risk of severe disease in preterm infants.
  • the C. perfringens postbiotic induced an increase in TEER and therefore monolayer integrity, meaning it would be suitable for such a therapeutic application. Additionally, it outperformed the B. infantis postbiotic, which had a weaker impact on TEER that could not be fully distinguished from negative and stimuli-only controls.
  • the 10% dose of the C. perfringens postbiotic showed stronger inhibition of cytokine secretion than the 10% dose of the B. infantis postbiotic.
  • the free short chain fatty acids were derivatized using methyl chloroformate in 1- propanol yielding propyl esters before subsequent liquid-liquid extraction into hexane and analysis on a SLB-5ms (30 x 0.25 mm x 1.0pm) column and detection using GC-EI-MS in SIMmode.
  • the analytes were quantified using 8-point calibration curves. Pairwise comparisons between Bifidobacterium and Clostridium for mean relative SCFAs levels were performed using an unpaired Student’s T test in R, with p ⁇ 0.05 set at the threshold for statistical significance.
  • SCFAs are considered to primarily be products of amino acid catabolism (Oliphant & Allen-Vercoe, Microbiome 2019, 7:1:91), rather than carbohydrate catabolism as with the other SCFAs, so their lower abundance in supernatants from cultures given a plentiful supply of HMOs is explicable.
  • the wider repertoire and lower uniformity of SCFA production within the Clostridium is further evidenced by the wide datapoint spread and confidence region of the genus during unsupervised ordination, compared to the tight grouping of Bifidobacterium samples (Fig. 13H).
  • Clostridium and Bifidobacterium predominantly cluster separately from one another during both ordination and dendrogram analyses, highlighting the distinctiveness of the SCFA production profiles of the two genera (Fig. 13H & I).
  • SCFAs are important to human health, as these compounds have a range of beneficial effects in the host, such as suppression of inflammatory cytokine secretion, promotion of intestinal barrier function and promotion of colonocyte metabolic function (Cifuentes et al., Current Research in Microbial Sciences 2024, 6:100219). They impact immune, nervous, and metabolic systems within the host. More specifically for neonates, SCFAs are associated with the health benefits to newborns of breastfeeding, as Bifidobacterium spp. are known to primarily metabolise HMOs into SCFAs (Stewart, Nat. Microbiol. 2021 , 6 (11), 1335-1336).
  • Clostridium can metabolise HMOs to produce greater quantities and a wider range of SCFAs than Bifidobacterium and that the genus contains greater heterogeneity in SCFA production than Bifidobacterium. Therefore, Clostridium could compensate for any absence of Bifidobacterium SCFA production, as they also produce high quantities of acetate, but the inverse is not true. Additionally, the heterogeneity amongst Clostridium raises the notion that it is important to identify the “right” Clostridium pro- or postbiotic, to ensure an optimal SCFA profile. Finally, these data show that the Clostridium postbiotics described herein will contain high quantities of various SCFAs, which may be mediating some of the beneficial activities outlined above.
  • Samples were prepared using the automated MicroLab STAR® system from Hamilton Company. Several recovery standards were added prior to the first step in the extraction process for QC purposes. To remove protein, dissociate small molecules bound to protein or trapped in the precipitated protein matrix, and to recover chemically diverse metabolites, proteins were precipitated with methanol under vigorous shaking for 2 min (Glen Mills GenoGrinder 2000) followed by centrifugation.
  • the resulting extract was divided into multiple fractions: two for analysis by two separate reverse phase (RP)/UPLC-MS/MS methods with positive ion mode electrospray ionization (ESI), one for analysis by RP/UPLC- MS/MS with negative ion mode ESI, one for analysis by HILIC/UPLC-MS/MS with negative ion mode ESI, while the remaining fractions were reserved for backup.
  • Samples were placed briefly on a TurboVap® (Zymark) to remove the organic solvent. The sample extracts were stored overnight under nitrogen before preparation for analysis.
  • QA/QC Several types of controls were analysed in concert with the experimental samples: a pooled matrix sample generated by taking a small volume of each experimental sample (or alternatively, use of a pool of well-characterized human plasma) served as a technical replicate throughout the data set; extracted water samples served as process blanks; and a cocktail of QC standards that were carefully chosen not to interfere with the measurement of endogenous compounds were spiked into every analysed sample, allowed instrument performance monitoring and aided chromatographic alignment. Instrument variability was determined by calculating the median relative standard deviation (RSD) for the standards that were added to each sample prior to injection into the mass spectrometers. Overall process variability was determined by calculating the median RSD for all endogenous metabolites (i.e., non-instrument standards) present in 100% of the pooled matrix samples. Experimental samples were randomized across the platform run with QC samples spaced evenly among the injections.
  • RSS median relative standard deviation
  • the extract was gradient eluted from a C18 column (Waters UPLC BEH C18- 2.1x100 mm, 1.7 pm) using water and methanol, containing 0.05% perfluoropentanoic acid (PFPA) and 0.1% formic acid (FA). Another aliquot was also analysed using acidic positive ion conditions, however it was chromatographically optimized for more hydrophobic compounds (PosLate).
  • the extract was gradient eluted from the same aforementioned C18 column using methanol, acetonitrile, water, 0.05% PFPA and 0.01% FA and was operated at an overall higher organic content.
  • the informatics system consisted of four major components, the Laboratory Information Management System (LIMS), the data extraction and peak-identification software, data processing tools for QC and compound identification, and a collection of information interpretation and visualization tools for use by data analysts.
  • the hardware and software foundations for these informatics components were the LAN backbone, and a database server running Oracle 10.2.0.1 Enterprise Edition.
  • Metabolon LIMS system The purpose of the Metabolon LIMS system was to enable fully auditable laboratory automation through a secure, easy to use, and highly specialized system.
  • the scope of the Metabolon LIMS system encompasses sample accessioning, sample preparation and instrumental analysis and reporting and advanced data analysis. All of the subsequent software systems are grounded in the LIMS data structures. It has been modified to leverage and interface with the in-house information extraction and data visualization systems, as well as third party instrumentation and data analysis software.
  • Raw data was extracted, peak-identified and QC processed using a combination of Metabolon developed software services (applications). Each of these services perform a specific task independently, and they communicate/coordinate with each other using industry-standard protocols. Compounds were identified by comparison to library entries of purified standards or recurrent unknown entities. Metabolon maintains a library based on authenticated standards that contains the retention time/index (Rl), mass to charge ratio (m/z), and fragmentation data on all molecules present in the library. Furthermore, biochemical identifications are based on three criteria: retention index within a narrow Rl window of the proposed identification, accurate mass match to the library +/- 10 ppm, and the MS/MS forward and reverse scores between the experimental data and authentic standards.
  • Rl retention time/index
  • m/z mass to charge ratio
  • biochemical identifications are based on three criteria: retention index within a narrow Rl window of the proposed identification, accurate mass match to the library +/- 10 ppm, and the MS/MS forward and reverse scores between the experimental data and authentic standards
  • the MS/MS scores are based on a comparison of the ions present in the experimental spectrum to the ions present in the library spectrum. While there may be similarities between molecules based on one of these factors, the use of all three data points is utilized to distinguish and differentiate biochemicals. More than 5,400 commercially available purified or in-house synthesized standard compounds have been acquired and analysed on all platforms for determination of their analytical characteristics. An additional 7000 mass spectral entries have been created for structurally unnamed biochemicals, which have been identified by virtue of their recurrent nature (both chromatographic and mass spectral). These compounds have the potential to be identified by future acquisition of a matching purified standard or by classical structural analysis. Metabolon continuously adds biologically-relevant compounds to its chemical library to further enhance its level of Tier 1 metabolite identifications.
  • tertium contained quantities of indoles that were absent from Bifidobacterium postbiotics (Fig. 15), specifically indole-3-acetaldehyde, indole- 3-carbaldehyde, tryptamine, 3-indoleglyoxylic acid and tryptophan.
  • Postbiotics from C. butyricum which cannot utilise HMOs also contained two of these compounds (tryptophan and indole-3-carbaldehyde) that were statistically different from the blank medium.
  • some postbiotics from the same three species also contained higher quantities of oxindolylalanine, however the inconsistency of these quantities between samples from the same species meant these levels were not found to be statistically significant (Fig. 15G).
  • Clostridium postbiotics contained raised quantities of polyamines, diamines and their precursors ornithine and citrulline (Fig. 16).
  • the polyamines agmatine and spermidine were produced within C. perfringens postbiotics, with C. tertium, C. butyricum, C. paraputrificum and C. baratii also having produced spermidine.
  • Bifidobacterium postbiotics lacked these compounds.
  • the diamine putrescine was produced only by C. tertium and C.
  • Clostridium postbiotics Fig. 17
  • Clostridium and Bifidobacterium postbiotics did however all share increased levels of phenyllactate, with the four Bifidobacterium spp., C. tertium and C. butyricum producing similarly high amounts, followed by C. perfringens and C. paraputrificum (Fig. 17B).
  • metabolites of interest were 3-hydroxybutyrate and trimethylamine N-oxide, both of which were raised in Clostridium postbiotics (Fig. 18) while being at very low abundance in all Bifidobacterium postbiotics.
  • C. perfringens and C. tertium postbiotics contained the greatest quantities of these two compounds, with C. paraputrificum and C. butyricum also containing raised levels of 3- hydroxybutyrate.
  • Indole-containing compounds are known to be produced from tryptophan catabolism by gut bacteria and they and their derivatives exert profound and beneficial effects on the host, such as promoting intestinal barrier function and inhibiting inflammation (Li et al., Front. Pharmacol. 2021, 12:769501). Bifidobacterium spp. are known to be producers of these compounds and it is thought they may help mediate the beneficial health effects associated with the genus (Sakurai et al., Microorganisms 2019, 7, 340). The finding in the metabolomics data that multiple of the Clostridium species produced these compounds within their postbiotics is therefore noteworthy.
  • lndole-3- acetaldehyde is considered to be chemically unstable and detectable levels of it are therefore thought to transient, with the compound usually converted into indole-3-acetate (Nutaratat et al., Arch Microbiol 2016, 198:429-437). If this conversion takes place, the resulting indole-3-acetate is known to be able to suppress inflammatory responses in immune cells (Li et al., Front. Pharmacol. 2021, 12:769501).
  • butyricum are able to synthesise this amino acid.
  • Other gut species would be able to metabolically cross-feed on tryptophan that is either supplemented in the gut via a postbiotic or being actively produced by a live probiotic strain. Such cross-feeding could accordingly increase the levels of beneficial indole compounds and further promote gut health.
  • Polyamines including spermidine and agmatine, are produced from lysine via cadaverine, and from arginine, ornithine and citrulline via putrescine (Sagar et al., Med. Sci. 2021, 9, 44). They are known to have numerous beneficial activities within the gut, such as increasing expression of tight junction proteins and reducing inflammatory immune responses (Rooks & Garrett, Nat Rev Immunol 2016, 16, 341-352; Pruss et al., Nat Metab 2022, 4, 19-28). Synthesis of polyamines has been identified as a vital gut microbiome function that is necessary for healthy postnatal development of the Gl tract.
  • infantis postbiotic samples demonstrates these pathways were active in this species, but the absence of raised spermidine, putrescine and agmatine suggests B. infantis is at least not as efficient a producer of polyamines as C. perfringens, C. tertium, C. butyricum and C. paraputrificum.
  • the lower levels of arginine in C. perfringens postbiotics further indicates strains of this species to be potent metabolisers of this amino acid and it appears this metabolism is channelled into ornithine and polyamine biosynthesis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pediatric Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention propose une composition probiotique pour améliorer le microbiome intestinal et/ou la santé intestinale d'un sujet comprenant au moins une espèce de Clostridium choisie parmi Clostridium perfringens, Clostridium baratii, Clostridium tertium et Clostridium paraputrificum. L'invention propose également des compositions postbiotiques à partir desdites espèces de Clostridium dans le même but. L'invention propose également des produits comprenant les compositions et des procédés d'utilisation des compositions.
PCT/GB2024/050842 2023-03-27 2024-03-27 Compositions probiotiques et postbiotiques, produits et leurs utilisations Ceased WO2024201041A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP24717762.9A EP4687932A2 (fr) 2023-03-27 2024-03-27 Compositions probiotiques et postbiotiques, produits et leurs utilisations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2304447.2 2023-03-27
GB2304447.2A GB2628547A (en) 2023-03-27 2023-03-27 Probiotic and postbiotic compositions, products and uses thereof

Publications (2)

Publication Number Publication Date
WO2024201041A2 true WO2024201041A2 (fr) 2024-10-03
WO2024201041A3 WO2024201041A3 (fr) 2024-12-05

Family

ID=86228213

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2024/050842 Ceased WO2024201041A2 (fr) 2023-03-27 2024-03-27 Compositions probiotiques et postbiotiques, produits et leurs utilisations

Country Status (3)

Country Link
EP (1) EP4687932A2 (fr)
GB (1) GB2628547A (fr)
WO (1) WO2024201041A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120753405A (zh) * 2025-09-10 2025-10-10 天赋能健康产业集团股份有限公司 短双歧杆菌后生元在清除自由基、缓解氧化衰老方面的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010666A1 (fr) 1996-09-10 1998-03-19 Societe Des Produits Nestle S.A. Aliment deshydrate contenant des bacteries lactiques
US8197872B2 (en) 2007-05-17 2012-06-12 The Regents Of The University Of California Human milk oligosaccharides to promote growth of beneficial gut bacteria
US8425930B2 (en) 2009-03-13 2013-04-23 The Regents Of The University Of California Prebiotic oligosaccharides
US9200091B2 (en) 2010-07-12 2015-12-01 The Regents Of The University Of California Bovine milk oligosaccharides
US20220313759A1 (en) 2016-07-01 2022-10-06 Evolve Biosystems, Inc. Method for facilitating maturation of the mammalian immune system

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
WO2007126816A2 (fr) * 2006-03-30 2007-11-08 Embrex, Inc. Procédés et compositions destinés à la vaccination des volailles
MX2015006491A (es) * 2012-11-23 2015-12-03 Seres Health Inc Composiciones bacterianas sinergicas y metodos de produccion y uso de las mismas.
WO2014167112A1 (fr) * 2013-04-12 2014-10-16 Danmarks Tekniske Universitet Sialidase mutante ayant une activité de trans-sialidase destinée à être utilisée en production de glycanes sialylés
US9956282B2 (en) * 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
WO2017074257A1 (fr) * 2015-10-26 2017-05-04 Nanyang Technological University Dérivés non viables de clostridium sporogenes utilisés comme agents thérapeutiques anti-cancéreux
US20180369297A1 (en) * 2015-12-14 2018-12-27 Metabogen Ab Treatment of intrahepatic cholestasis and related liver diseases
CN109275911A (zh) * 2018-11-02 2019-01-29 梁余成 一种饲用益生菌片剂及其制备方法
CN114222584A (zh) * 2019-07-30 2022-03-22 辉宝动物保健公司 一种用于禽类粘膜施用的组合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010666A1 (fr) 1996-09-10 1998-03-19 Societe Des Produits Nestle S.A. Aliment deshydrate contenant des bacteries lactiques
US8197872B2 (en) 2007-05-17 2012-06-12 The Regents Of The University Of California Human milk oligosaccharides to promote growth of beneficial gut bacteria
US8425930B2 (en) 2009-03-13 2013-04-23 The Regents Of The University Of California Prebiotic oligosaccharides
US9200091B2 (en) 2010-07-12 2015-12-01 The Regents Of The University Of California Bovine milk oligosaccharides
US20220313759A1 (en) 2016-07-01 2022-10-06 Evolve Biosystems, Inc. Method for facilitating maturation of the mammalian immune system

Non-Patent Citations (38)

* Cited by examiner, † Cited by third party
Title
BARCIK ET AL., CURRENT OPINION IN IMMUNOLOGY, vol. 48, 2017, pages 108 - 113
BECK, NATURE MICROBIOLOGY, vol. 7, 2022, pages 1525 - 1535
BHATTARAI ET AL., CELL HOST & MICROBE, vol. 23, 2018, pages 775 - 785
BJORNSDOTTIR-BUTLER ET AL., J. FOOD PROT., vol. 76, 2013, pages 7
BOSTICK ET AL., CURRENT OPINION IN IMMUNOLOGY, 2022, pages 76
CARTMAN, FUTURE MICROBIOL., vol. 6, no. 9, 2011, pages 969 - 971
CHEN ET AL., M J PERINATOL, vol. 38, no. 11, 2021, pages 1142 - 1149
CIFUENTES ET AL., CURRENT RESEARCH IN MICROBIAL SCIENCES, vol. 6, 2024, pages 100219
DEITEREN ET AL., BRITISH JOURNAL OF PHARMACOLOGY, vol. 172, 2015, pages 1165 - 1178
FOFANOVA ET AL., BIORXIV, 2019, pages 555755
GHOSH ET AL., CELL MOL GASTROENTEROL HEPATOL, vol. 11, 2021, pages 1463 - 1482
GOA ET AL., MBIO, vol. 6, no. 6, 2015, pages 01358 - 15
GUO ET AL., JOURNAL OF ANIMAL SCIENCE AND BIOTECHNOLOGY, 2020
HALEMARHAM, THE HARPER COLLINS DICTIONARY OF BIOLOGY, HARPER PERENNIAL, NY, 1991
HENRICK ET AL., CELL, vol. 184, no. 15, 22 July 2021 (2021-07-22)
HO ET AL., JOURNAL OF FUNCTIONAL FOODS, vol. 64, 2020, pages 103571
HUANG ET AL., ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, vol. 206, 1993
KIU ET AL.: "Dissemination and pathogenesis of toxigenic Clostridium perfringens strains linked to neonatal intensive care units and Necrotising Enterocolitis", BIORXIV PREPRINT, 2021
LAURSEN ET AL., NAT MICROBIOL., 2021
LI ET AL., FRONT. PHARMACOL., vol. 12, 2021, pages 769501
MA ET AL., MBIO, vol. 13, 2022, pages 01299 - 22
NEEDHAM ET AL., NATURE, vol. 602, 2022, pages 647 - 653
NING ET AL., FOOD CHEMISTRY, vol. 228, 2017, pages 533 - 540
NUTARATAT ET AL., ARCH MICROBIOL, vol. 198, 2016, pages 429 - 437
PRUSS ET AL., NAT METAB, vol. 4, 2022, pages 19 - 28
ROOKSGARRETT, NAT REV IMMUNOL, vol. 16, 2016, pages 341 - 352
SAGAR ET AL., MED. SCI., vol. 9, 2021, pages 44
SAKURAI ET AL., MICROORGANISMS, vol. 7, 2019, pages 340
SANIDAD ET AL., SCI. IMMUNOL., vol. 9, 2024, pages 4775
SILVA-ANDRADE ET AL., MICROORGANISMS, vol. 10, no. 2, February 2022 (2022-02-01), pages 213
SINGLETONSAINSBURY: "Dictionary of Microbiology and Molecular Biology", 1994, JOHN WILEY AND SONS
SKONDRA ET AL., J AAPOS., vol. 24, no. 4, August 2020 (2020-08-01), pages 236 - 238
SRINIVASAN ET AL., J LAB AUTOM., vol. 20, no. 2, April 2015 (2015-04-01), pages 107 - 126
STEWART ET AL., METHODS MOL BIOL., vol. 2121, 2020, pages 185 - 198
STEWART, NAT. MICROBIOL., vol. 6, no. 11, 2021, pages 1335 - 1336
SUN ET AL., BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 519, 2019, pages 351 - 357
ZHANG ET AL., APPL ENVIRON MICROBIOL., vol. 75, no. 4, February 2009 (2009-02-01), pages 1080 - 1087
ZHANGDAVIES, GENOME MED., vol. 8, 2016, pages 46

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120753405A (zh) * 2025-09-10 2025-10-10 天赋能健康产业集团股份有限公司 短双歧杆菌后生元在清除自由基、缓解氧化衰老方面的应用

Also Published As

Publication number Publication date
GB202304447D0 (en) 2023-05-10
WO2024201041A3 (fr) 2024-12-05
EP4687932A2 (fr) 2026-02-11
GB2628547A (en) 2024-10-02

Similar Documents

Publication Publication Date Title
JP7266636B2 (ja) 食物アレルギーの処置および／または防止のための治療用微生物叢
Yan et al. A ropy exopolysaccharide producing strain Bifidobacterium longum subsp. longum YS108R alleviates DSS-induced colitis by maintenance of the mucosal barrier and gut microbiota modulation
US10918653B2 (en) Bovine milk oligosaccharides
US11318175B2 (en) Method for facilitating maturation of the mammalian immune system
KR101353692B1 (ko) 프로바이오틱 및 프리바이오틱 성분 및 무기 염을 락토페린과 함께 포함하는 조성물
US10716816B2 (en) Activated bifidobacteria and methods of use thereof
EP3812452A1 (fr) Bifidobacterium lactis bl-99 et application associée
CA2973223A1 (fr) Compositions probiotiques et prebiotiques, et leurs procedes d'utilisation pour la modulation du microbiome
HK1044964A1 (zh) 用於治療炎性疾病的雙岐桿菌
US20240293483A1 (en) Probiotic composition for the treatment of increased intestinal permeability
US20240226191A1 (en) Compositions and methods for treating disease
US11752178B2 (en) Methods for the isolation of microbes with enhanced persistance and compositions with such microbes
EP4687932A2 (fr) Compositions probiotiques et postbiotiques, produits et leurs utilisations
JP2022504185A (ja) 細菌株を含む組成物
US20230310519A1 (en) Use of adlercreutzia bacteria for the treatment of inflammatory diseases
WO2024130119A9 (fr) Compositions symbiotiques pour la production d'acides gras à chaîne courte
Zhang et al. Gut Microbiota and Health
Sako The world's oldest probiotic: perspectives for health claims.
EP4541362A1 (fr) Souches probiotiques à utiliser dans le traitement de l'obésité
CN120665783A (zh) 一株两歧双歧杆菌及在制备免疫调节、修复肠道屏障的制剂中的应用
Lundberg An exploratory journey into probiotic interactions
EA052600B1 (ru) Пробиотическая композиция для лечения повышенной кишечной проницаемости
Zhao Strain-specific Effects of Bifidobacterium Animalis. Lactis on in Vitro Models of Gastrointestinal Inflammation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2024717762

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024717762

Country of ref document: EP

Effective date: 20251027

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24717762

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2024717762

Country of ref document: EP

Effective date: 20251027

ENP Entry into the national phase

Ref document number: 2024717762

Country of ref document: EP

Effective date: 20251027

ENP Entry into the national phase

Ref document number: 2024717762

Country of ref document: EP

Effective date: 20251027

ENP Entry into the national phase

Ref document number: 2024717762

Country of ref document: EP

Effective date: 20251027

ENP Entry into the national phase

Ref document number: 2024717762

Country of ref document: EP

Effective date: 20251027

ENP Entry into the national phase

Ref document number: 2024717762

Country of ref document: EP

Effective date: 20251027

ENP Entry into the national phase

Ref document number: 2024717762

Country of ref document: EP

Effective date: 20251027

WWP Wipo information: published in national office

Ref document number: 2024717762

Country of ref document: EP